

CURRICULUM VITAE

Franco Battista Ennio Folli, M.D. Ph.D.

WORK ADDRESS:

Dipartimento di Scienze della Salute
ASST – Santi Paolo e Carlo
Universita' degli Studi di Milano
Via A. di Rudini 8
20142 Milano
Italy
Tel. +39-02-50323192
Fax. +39-02-50323001
Cell. +39-331-8706122
Email: franco.folli@unimi.it

Department of Medicine / Diabetes Division
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, TX
USA
e-mail: folli@uthscsa.edu

Departamento De Clinica Medica
Obesity Comorbidities Research Center
University of Campinas
Rua Tessalia Vieira de Camargo, 126
13083-887 Campinas, Sao Paulo State
Brazil

HOME ADDRESS/
RESIDENCE :

Via J.F. Kennedy 36
20097 San Donato Milanese
Milano
Italy

CITIZENSHIP:

Italy and USA (*naturalized*)

FAMILY:

2 children, Natalie Maria Cristina Folli and Angelo Folli

EDUCATION:

1974-1979 *Maturita' Scientifica* – Liceo di San Donato Milanese (60-60 /Highest Honours - *Valedictorian*)
1979-1986 M.D., Università di Milano, Italy (*Summa cum laude*)
1986-1989 Postgraduate training (Specialita') in Diabetes and Metabolic Diseases, Università di Milano, Italy (*Summa cum laude*)
1990-1994 Ph.D. Clinical Pathysiology, Università di Milano e Padova, Italy (*Highest Honours*)

MANDATORY MILITARY SERVICE (Italy):

1988-89 Corporal in the Italian Air Force – Health Division

“FELLOWSHIPS” AND HONOURS:

Internship and Residencies:

- 1986-1987 Fellow in Internal Medicine, University of Milano, School of Medicine, Milano, Italy (H.S. Raffaele Research Fellowship)
- 1987-1988 Fellow in Clinical Immunology, University College and Middlesex School of Medicine, London, U.K. (*Mentor: Gian Franco Bottazzo MD*) (H.S. Raffaele Research Fellowship)
- 1988-1989 Fellow in Internal Medicine, University of Milano, School of Medicine, Milano, Italy

Clinical and Research Fellowships:

- 1990 Postdoctoral Fellow in Cell Biology, Yale University, Medical School, New Haven, CT, USA (*Mentor: Pietro De Camilli M.D.*)
- 1991 Postdoctoral Fellow in Internal Medicine, University of Milano, School of Medicine, Milano, Italy
- 1991-1993 Research Fellow in Internal Medicine, Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (*Mentor: C. Ronald Kahn M.D.*)

Honours:

- March 1983-August 1983 Visiting Medical Student at the Endocrine Division, Dept of Medicine, East Carolina University, Greenville, NC (*Tutors: Jose' F. Caro MD and Madhur Sinha PhD*)
- 1988 Upjohn Prize for Pharmacology
- 1988 Istituto Scientifico San Raffaele Research Fellowship
- 1990 Istituto Scientifico San Raffaele Research Fellowship
- 1992 Trainee Investigator Award, American Federation for Clinical Research
- 1996 Trainee Investigator Award, American Federation for Clinical Research
- 2000 G.B. Morgagni Prizes, Young Investigator Award- Silver Medal
- 2005 Lettura SID Alcmeone e Premio diricerca Servier, Societa' Italiana di Diabetologia

Google Scholar Profile:

<https://scholar.google.com.br/citations?user=UriDBz4AAAAJ&hl=en>

Top Italian Scientist

https://topitalianscientists.org/tis/2032/Franco_Folli__Top_Italian_Scientist_in_Clinical_Sciences

ORCID ID:

<https://orcid.org/0000-0001-9824-5222>

Editorial Boards Membership:

- 2011- Journal of Diabetes Mellitus
- 2011- Plos One (*Academic Editor*)
- 2012- Journal of Diabetes and its Complications

2014- Frontiers in Cardiovascular Diseases
 2015-2018 Diabetes Care
 2014- Acta Diabetologica
 2014- Current Diabetes Reviews (*Regional Editor-North America*)
 2012- Journal of Translational Medicine

MEMBERSHIP TO SCIENTIFIC SOCIETIES AND OTHER SCIENTIFIC /ACADEMIC ACTIVITIES:

1995-2000 Member, European Society for Clinical Investigation
 2000-2004 Member, Società Italiana di Neuroimmunologia
 2001-present Member American Diabetes Association
 2004-present Member Società Italiana Diabetologia
 1993-present Scientific reviewer for the following journals: Molecular Endocrinology, Endocrinology, Acta Diabetologica, Diabetes Care, Diabetes, Journal of Neurology, Neurosurgery and Psychiatry, Journal of Neuroimmunology Journal of Clinical Investigation, Nature, JCEM, Circulation, Proceedings of the National Academy of Science, American Journal of Transplantation, Atherosclerosis, Journal of the American Geriatric Society, Diabetologia, Molecular Vision, Journal of the American College of Cardiology.
 1998-present MURST (Ministero Università' e Ricerca Scientifica) "ad hoc" reviewer for diabetes mellitus and autoimmune diseases grant applications.
 2006-2007 Abstract Reviewer American Diabetes Association Meeting – Chicago 2007 and San Francisco 2008
 2008 Grant Reviewer FONDAZIONE CARIPLO, Milano, Italy
 2008- present Grant Reviewer FONDAZIONE ROMA, Roma, Italy
 August 2006-present Member, Institutional Animal Care and Use Committee, UTHSCSA
 August 2007 – 2010 Member, Medical School Admission Committee, UTHSCSA
 August 2008- present Member Committee of Graduate Studies (COGS) Biochemistry Track and Biochemistry and Metabolic Disorders Track, UTHSCSA
 April 2010 - present Member, MD/PhD Advisory Committee, UTHSCSA
 2010- NIH-NIDDK Stage 1 Editorial Board Reviewer
 2011- NIH-NIDDK Seeding R24 – Special Emphasis Panel
 2012- NIH-NIDDK
 2013-2018 Member of Board of Advisors of the OCRC (Obesity and Comorbidities Research Center), University of Campinas, Brazil - :

- David A. Calhoun
- Ajay Chawla
- Miriam Cnop
- Marcelo Di Carli
- Decio L. Eizirik
- Franco Folli
- Steven E. Kahn
- Peter Libby
- Michael W. Schwartz

RESEARCH INTERESTS:

1. Mechanisms of insulin action, resistance and β -cell failure. Pathogenesis of non-insulin-dependent diabetes mellitus (T2DM).
2. Clinical-mechanistic trials of new pharmacological treatments and bariatric surgeries for the preventions and treatment of type 2 and type 1 diabetes mellitus and their complications.
3. Pathogenesis of insulin-dependent diabetes mellitus (T1DM) and Stiff-man syndrome.

4. Biology of regulated secretion in the endocrine pancreas and central nervous system
5. Pathogenesis of diabetic vascular complications
6. Central nervous system paraneoplastic syndromes
7. Tyrosine kinases and mechanisms of intracellular signal transduction
8. Proteomics approach to assess regulation in protein expression in diabetes mellitus and associated disease states
9. Development of non-human primate models for the study and development of novel therapeutic approaches of obesity, insulin resistance and type 2 diabetes mellitus
10. Mechanisms of action of GLP-1 receptor agonists in humans and non-human primate models of type 2 diabetes mellitus.
11. Morbid obesity, molecular mechanisms of pathogenesis, prevention and treatment.

PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSABILITIES:

- November 2018 – present Director Diabetes and Metabolism Departmental Unit- ASST Santi Paolo e Carlo - Milano
- May 1994 – July 2005 Senior Registrar in Internal Medicine/Emergency Medicine, Senior Investigator, Department of Internal Medicine HS Raffaele, Milano)
- 1999 – July 2005 Head, Endocrine Research Unit III, HS Raffaele, Milano
- 1999 – July 2005 Consultant in Diabetes and Metabolic Diseases, HS Raffaele, Milano.
- 2001 – July 2005 Consultant in Diabetes and Metabolic Diseases, Department of Obstetric and Gynecology, HS Raffaele, Milano

TEACHING/ACADEMIC POSITION:

- 1991 – 1993 Research Fellow in Medicine, Joslin Diabetes Center, Harvard Medical School, Boston (Mentor: Dr. C. Ronald Kahn)
- 1994 – 1996 Visiting Investigator; Joslin Diabetes Center Harvard Medical School, Boston (Laboratory of Dr. C. Ronald Kahn)

TEACHING/ACADEMIC POSITION:

- September 1991 – Dec. 1993 Research Fellow in Medicine, Joslin Diabetes Center, Harvard Medical School, Boston (Mentor: Dr. C. Ronald Kahn)
- September 1994 – Feb. 1996 Visiting Investigator; Joslin Diabetes Center Harvard Medical School, Boston (Laboratory of Dr. C. Ronald Kahn)
- September 1996 – July 2005 Tutor Internal Medicine, Università di Milano, Italy
- September 1994 – July 2002 Adjunct Professor, – Postgraduate School of Endocrinology and Metabolic Diseases, Università di Milano, Italy
- September 2001 – July 2002 Adjunct Professor of Internal Medicine, Dental School, Università di Milano
- January to September 2002 Assistant Professor of Internal Medicine, University of Milano (*vincitore di concorso per titoli ed esami*)
- July 2005 – May 2009 Associate Professor of Medicine
Director of Metabolic and Molecular Research,
Diabetes Division, Dept. of Medicine,

University of Texas Health Science Center at San Antonio
San Antonio, Texas

September 2009 – Aug.2016 Professor of Medicine (*with Tenure*)
Diabetes Division, Dept.of Medicine
University of Texas Health Science Center at San Antonio
San Antonio, Texas

Director of Metabolic and Molecular Research,
Diabetes Division, Dept.of Medicine
University of Texas Health Science Center at San Antonio
San Antonio, Texas

July 2006- June2010 Associate Scientist (Adjunct)
Dept of Genetics
Southwest Foundation for Biomedical Research
San Antonio, Texas

March 2008-Sept. 2011 Associate Professor of Pharmacology (Adjunct)
University of Texas Health Science Center at San Antonio,
San Antonio, Texas

June 2010-present Scientist (Adjunct)
Dept of Genetics
Southwest Foundation for Biomedical Research
San Antonio, Texas

November 2013 – present Visiting Professor of Medicine
Departamento de Clinica Medica
Obesity Comorbidities Research Center
University of Campinas
Campinas, San Paolo
Brazil

August 2016 - present Professor of Endocrinology
(Professore Ordinario – Settore MED13)
Dipartimento di Scienze della Salute
Facolta' di Medicina e Chirurgia
Universita' di Milano,
Italy.

November 2018 – present Director
Diabetes and Metabolic Diseases
ASST Santi Paolo e Carlo
Ospedale San Paolo e San Carlo
Milano
Italy

Aug. 2016 - present Professor of Medicine (*Adjunct*)
Diabetes Division, Dept.of Medicine
University of Texas Health Science Center at San Antonio
San Antonio, Texas

November 2020 – present President
Bachelor Degree in Dietetics
Universita' degli Studi di Milano
Italy

November 2018 – present President
Semeiology for Apparatus II
Faculty of Medicine
Universita' degli Studi di Milano
Italy

INVENTIONS/PATENTS/PATENT APPLICATIONS:

- 1- US patent 5.512.447: “Improved Methods for the diagnosis and treatment of diabetes” S. Baekkeskov, H.V. Aanstoot, F. Folli, M.Solimena, P.De Camilli.
- 2- European Patent EP1663395: Multisystem therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent; F. Folli, P. Manfredi, G. Gonzales)
- 3- US Patent 7,718,386 B1:” Methods for the diagnosis of diabetes” S. Baekkeskov, H.V. Aanstoot, F. Folli, M.Solimena, P.De Camilli
4. US patent 8,722,343 _ Methods and compositions for the Diagnosis and treatment of Diabetes. C. Perego, E. Di Cairano, AM Davalli, F. Folli
5. 2004: US patent application 10/868,227: Multi-system therapy for diabetes, the metabolic syndrome and obesity. F. Folli, P. Manfredi, G. Gonzalez
6. 2006: Invention disclosure: A method for the screening, identification, and detection of molecular targets, of compounds for the treatment of conformational/amyloidogenic/degenerative diseases (CADDs). F. Folli, L. Perego, AM Davalli
7. 2006: US patent application: Daily dosage regimen for treating diabetes, obesity and metabolic syndrome. F. Folli, P. Manfredi, G. Gonzalez
- 8.(WO/2007/011524) Daily dosage regimen for treating diabetes, obesity, metabolic syndrome and polycystic ovary syndrome. F. Folli, P. Manfredi, G. Gonzalez.
9. 2010:WO/2010/057647) Methods and compositions for the diagnosis and treatment of diabetes. C. Perego, E. Di Cairano, AM Davalli, F. Folli.

CLINICAL TRIALS:

- 1) PROACTIVE Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Role: Proactive Investigator (HS Raffaele - Milano-Italy)
- 2) Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes (PIO-TACE). Clinicaltrial.gov ID: NCT01223196. Role: Principal Investigator.

INVITED LECTURES:

1990 Invited Lecture, East Carolina University, Greenville, NC
1994 Invited Lecture, Novo Nordisk Research Laboratory
 Copenhagen, Denmark
1994 Invited Lecture, Gottingen University, Germany
1995 Invited Lecture, Dept of Medicine/Endocrine Section
 Seminars, Yale University
1996 Invited Speaker, Societa' Italiana di Diabetologia, Napoli, Italy

- 1997 Invited Lecture, Postgraduate School of Endocrinology and Metabolic Diseases, Università di Verona
- 1997 Invited Lecture, “Corsi Residenziali di Neuroimmunologia” Bergamo, Italy
- 1997 Invited Lecture, IDF-EASD meeting, Helsinki, Finland
- 1998 Invited Speaker, HS Raffaele International Disease Meeting, Milano Italy
- 1998 Invited Speaker, University of Geneva, Switzerland
- 2000 Invited Speaker, The 34th ESCI Annual Scientific Meeting, Milano Italy
- 2000 Invited Speaker, Società Italiana di Diabetologia, Bari, Italy
- 2001 Invited Speaker, CNR Institute of Pharmacology, Milano, Italy
- 2002 Invited Speaker 1st Symposium on Diabetes and Metabolism, Campinas, Brazil
- 2004 Invited Speaker, Congresso Nazionale Società Italiana di Diabetologia, Roma, Italy
- 2004 7th Congress of Diabetes and Metabolism of Sao Paulo State, Sao Jose do Campos, Brazil
- 2004 Invited Speaker, 1st Congress on Bariatric Surgery, Bergamo, Italy
- 2004 Invited Speaker, Società Italiana di Diabetologia, Sezione Lombardia, Milano
- 2004 Invited Speaker, Società Italiana di Diabetologia, Annual Meeting, Roma
- 2005 Invited Lecture, Postgraduate School of Endocrinology and Metabolic Diseases, Università di Padova
- 2005 Invited Lecture, Postgraduate School of Endocrinology of Catanzaro, “Magna Grecia”
- 2005 Invited Speaker, Congresso Società Italiana di Diabetologia, Riccione, Italy
- 2006 Invited Speaker SID meeting Milano, EASD-SID “Omics” Symposium
- 2007 Invited Speaker, University of Dresden, Germany
- 2008 Invited Speaker, University of Milano, Italy
- 2009 Invited Speaker, “I ragazzi di Via Olgettina”, Università Vita-Salute HS Raffaele, Milano, Italy
- 2010 Invited Speaker, American Diabetes Association, 70th Scientific Sessions, Orlando, Florida
- 2010 Invited Lecture, Endocrine Grand Rounds, University of Texas Medical Branch, Galveston, TX
- 2011 Invited Speaker, Experimental Biology Meeting 2011, Washington, DC
- 2011 Invited Speaker, American Society of Nuclear Medicine, San Antonio, TX
- 2011 Invited Speaker, ABCD meeting, Viareggio, Italy
- 2011 Invited Speaker, IDF Meeting, Dubai, UAE
- 2012 Invited Speaker, “Debate 2012”, Bangalore, India
- 2012 Invited Lecture, Endocrine Grand Rounds, University of Texas Medical Branch, Galveston, TX
- 2012 Invited Lecture, II Simposio Academico De Diabetes Mellitus, San Paulo, Brazil
- 2013 Invited Lecturer, RSSDI 2013 - 41st Annual Conference of Research Society for Study of Diabetes in India, New Delhi, India
- 2013 Invited Speaker: “Pancreatic Pleiotropic Effects of Exenatide/ Exendin-4, a GLP-1 receptor agonist in the baboon, a non-human primate model of Obesity and Type 2 diabetes mellitus.”, Gordon Research Conference “Pancreatic Diseases. From Molecules to Patients” Mount Holyoke College, South Hadley, MA, USA.
- 2013 Invited Speaker, “Kahn Scholar Colloquium”- October 30, 2013,

- 2013 Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
Invited Speaker, “Obesidade e Diabetes”- November 28, 2013
- 2013 University of Campinas, School of Medicine, Campinas, S.P., Brazil.
Invited Speaker, The 8th Annual International Conference of The
Arabic Association for the Study of Diabetes & Metabolism (AASD),
December 17-18, Cairo, Egypt.
- 2014 Invited Speaker, 11 Congresso Paulista de Diabete e Metabolismo,
May 2014, Guarujá, S.P, Brazil
- 2014 Invited Speaker, 19 Congresso Brasileiro Multidisciplinar em
Diabetes, July 27 2014, São Paulo, S.P., Brazil
- 2014 Invited Speaker, 1 Simposio Obesity and Comorbidities Research
Center, August 21 2014, University of Campinas, Campinas SP,
Brazil
- 2015 Invited Speaker, “International Symposium about Metabolic
Syndrome” Albert Einstein Reseach and Education Institute, Sao
Paulo, March 27-28
- 2015 Invited Speaker, International Meeting on Metabolism, University of
Limeira, Limeira, Sao Paulo State, Brazil, May 28-29
- 2015 Invited Speaker, Pontificia Universidade de Campinas, Campinas,
Sao Paulo State, Brazil, June 12
- 2015 Invited Speaker, XX Congresso da Sociedade Brasileira de Diabetes,
Puerto Alegre, Brazil, November 11-13
2015.
- 2016 Invited Speaker “Milano Transplant Meeting”, May 13, 2016
- 2017 Invited Speaker “Experimental Biology Meeting, April 22-26, 2017
Chicago, IL. USA
- 2017 Invited Speaker , XIII Sao Paulo Congress of Endocrinology and
Metabolism, São Paulo, SP, Brazil, May 25-27, 2017.
- 2017 Invited Speaker, Milano Diabete – Therapies and Beyond, Milano 24-
25 Novembre 2017

PUBLICATIONS

1. Caro JF, Folli F, Cecchin F, Sinha MK. Chemical mediator of insulin action stimulates lipid synthesis and down regulates the insulin receptors in primary cultures of rat hepatocytes. *Biochem Biophys Res Commun* 115(1):375-82, 1983. PMID: 6311211
2. Folli F, Sinha MK, Brancaccio D, Caro JF. Insulin resistance in uremia: in vitro model in the rat liver using human serum to study mechanisms. *Metabolism* 35(11):989-98, 1986. PMID: 3534520
3. Caro JF, Cecchin F, Folli F, Marchini C, Sinha MK. Effects of T3 on insulin action, insulin binding and insulin receptor kinase activity in primary cultures of rat hepatocytes. *Horm. Metab. Res.* 20(6):327-32, 1988. PMID: 2843448

4. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. *New Engl. J. Med.* 318(16):1012-20, 1988. PMID: 3281011
5. Vicari AM, Folli F, Pozza G, Comi GC, Comola M, Canal N, Besana C, Borri A, Tresoldi M, Solimena M, De Camilli P. Plasmapheresis in the treatment of stiff-man syndrome. (*Letter to the editor*). *New Engl. J. Med.* 320(22):1499, 1989. PMID: 2716805
6. Solimena M, Folli F. Stiff-man syndrome e diabete mellito di tipo I: una comune patogenesi ? [Stiff-man syndrome and type I diabetes mellitus: a common autoimmune pathogenesis?] *Ann. Ist. Super. Sanita* 24(4):583-86., 1988. PMID: 3218808
7. Solimena M, Folli F, Morello F, Toso V, De Camilli P. A second case of Stiff-man syndrome and epilepsy with autoantibodies against GABA-ergic system. *In: Berardelli A, Benecke R., Manfredi M. Marsden C.D. eds. Motor Disturbances II*, Academic Press, New York: pp 415-417, 1990.
8. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. *New Engl. J. Med.* 322(22):1555-60, 1990. PMID: 2135382
9. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olsen H, De Camilli P. The 64K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. *Nature* 347(6289):151-56, 1990. PMID: 1697648
10. Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. *EMBO J.* 10(5):1275-84, 1991. PMID: 2022191
11. Folli F, Saad MJA, Backer JM, Kahn CR. Insulin stimulation of phosphatidylinositol 3-kinase activity and association with insulin receptor substrate-1 in liver and muscle of the intact rat. *J. Biol. Chem.* 267(31):22171-77, 1992. PMID: 1385396
12. Folli F, Solimena M, De Camilli P, Pozza G. Sindrome dell' uomo rigido (Stiff-man syndrome). *Enciclopedia Medica Italiana UTET*, 1992.
13. Kahn CR, Araki E, Saad MJA, Folli F, Zoppini G, Huertas P. Molecular aspects of insulin action, insulin resistance and their relationship to atherosclerosis. P.C. Weber and A. Leaf, Editors *Atherosclerosis Reviews*. Raven Press, New York, vol. 25:209-224, 1993.
14. Kahn CR, White MF, Shoelson SE, Backer JM, Araki E, Cheatham B, Csemery P, Folli F, Goldstein BJ, Huertas P, Rothenberg PL, Saad MJA, Siddle K, Sun XJ, Wilden PA, Yamada K, Kahn S. The insulin receptor and its substrate: molecular determinants of early events in insulin action. *Recent Prog. Horm. Res.* 48:291-339, 1993. PMID: 7680139
15. Kahn CR, Folli F. Molecular determinants of insulin action. *Horm. Res.* 39 (suppl.3):93-101, 1993. PMID: 7505252
16. Pellegatta F, Folli F, Ronchi P, Caspani L, Galli L, Vicari AM. Deranged platelet calcium homeostasis in poorly controlled IDDM patients. *Diabetes Care* 16(1):178-83, 1993. PMID: 8422772
17. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetto F, Bates D, Cartlidge N, Bottazzo GF, Piccolo G, DeCamilli P. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. *New Engl. J. Med.* 328(8):546-51, 1993. PMID: 8381208
18. De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, Meinck HM, Austoni M, Fassetto F, Bottazzo GF, Bates D, Cartlidge N, Solimena M, Kilimann MW. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. *J. Exp. Med.* 178(6):2219-23, 1993. PMID: 8245793
19. Folli F, Saad MJA, Backer JM, Kahn CR. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. *J. Clin. Invest.* 92(4):1787-94, 1993. PMID: 7691886
20. Saad MJA, Folli F, Kahn J, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1 and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone treated rats. *J. Clin. Invest.* 92(4): 2065-72, 1993. PMID: 7691892
21. Saad MJA, Folli F, Araki E, Hashimoto N, Csemery P, Kahn CR. Regulation of insulin receptor, insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-F442A

- adipocytes. Effects of differentiation, insulin, and dexamethasone. *Mol. Endocrinol.* 8(5):545-57, 1994. PMID: 7520127
22. Folli F, Bonfanti L, Renard E, Kahn CR, Merighi A. Insulin receptor substrate- 1 (IRS-1) distribution in the rat central nervous system. *J. Neurosci.* 14(11 Pt 1):6412-22, 1994. PMID: 7965046
 23. Vicari AM, Monzani ML, Pellegatta F, Ronchi P, Folli F. Platelet calcium homeostasis is abnormal in patients with severe arteriosclerosis. *Arterioscler. Thromb.* 14(9):1420-24, 1994. PMID: 8068602
 24. Saad MJA, Folli F, Kahn CR. Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in FAO hepatoma cells. *Endocrinology* 136(4):1579-88, 1995. PMID: 7895667
 25. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. *J. Clin. Endocrinol. & Metab.* 80(11):3311-20, 1995. PMID: 7593444
 26. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn .R. In vivo and in vitro studies of vanadate in humans and rodents with diabetes mellitus. *Mol. Cell. Biochem.* 153(1-2):217-31, 1995. PMID: 8927042
 27. Vicari AM, Taglietti MV, Pellegatta F, Ronchi P, Melandri M, Spotti D, Folli F. Deranged platelet calcium homeostasis in diabetic patients with end-stage renal failure. A possible link to increased cardiovascular mortality? *Diabetes Care* 19(10):1062-66, 1996. PMID: 8886550
 28. Folli F, Ghidella S, Bonfanti L, Kahn CR, Merighi A. The early intracellular signaling pathway for the insulin/insulin like growth factor receptor family in the mammalian central nervous system. *Mol. Neurobiol.* 13(2):155-83, 1996. PMID: 8938649
 29. Velloso LA, Folli F, Sun XJ, White MF, Saad MJA, Kahn CR. Cross-talk between insulin and angiotensin signaling systems. *Proc. Natl. Acad. Sci., USA* 93(22):12490-95, 1996. PMID: 8901609
 30. Folli F. Il possibile ruolo di IRS-1 nella patogenesi dell'insulino-resistenza del diabete mellito non-insulino-dipendente. *Il Diabete*, 1996.
 31. Folli F, Saad MJA, Kahn CR. The insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. *Acta Diabetol.* 33(3):185-192, 1996. PMID: 8904923
 32. Folli F, Alvaro D, Gigliozzi A, Bassotti C, Kahn CR, Pontiroli AE, Capocaccia L, Jezequel AM, Benedetti A. Regulation of endocytic-transcytotic pathways and bile secretion by phosphatidylinositol 3-kinase in rats. *Gastroenterology* 113(3):954-65, 1997. PMID: 9287989
 33. Folli F, Kahn CR, Bouchie J, Hansen H, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. *J. Clin. Invest.* 100(9):2158-69, 1997. PMID: 9410892
 34. Folli F, Ponzoni M, Vicari AM. Paraneoplastic autoimmune xerostomia. (*Letter to the Editor*). *Ann. Intern. Med.* 127(2):167-8, 1997. PMID: 9230018
 35. Manfredi PM, Herskovitz S, Folli F, Pigazzi A, Swerdlow ML. (1998). Spinal epidural abscess: treatment options. *Eur. Neurol.* 40(1): 58-60. PMID: 9729116
 36. Folli F. Stiff man syndrome, 40 years later. *J Neurol. Neurosurg. Psychiatry* 65(5): 618, 1998. PMID: 9810927
 37. Velloso LA, Carvalho CR, Rojas FA, Folli F, Saad MJ. Insulin signaling in heart involves insulin receptor substrates- 1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway. *Cardiovasc. Res.* 40(1): 96-102, 1998. PMID: 9876321
 38. Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi GC, Camba L. Acute promyelocytic leukemia following mitoxantrone as a single agent for the treatment of multiple sclerosis. *Leukemia* 12(3): 441-2, 1998. PMID: 9529141
 39. Vicari AM, Ponzoni M, Alberetto M, Martani C, Pontiroli AE, Folli F. Erythrocytosis in a patient with chronic obstructive pulmonary disease. *Haematologica* 83(2):183-6, 1998. PMID: 9549929
 40. Pontiroli AE, Folli F. Is it worth to treat diabetes? Lessons from the UKPDS. United Kingdom Prospective Diabetes Study. *Acta Diabetol.* 35(4):170-1, 1998. PMID: 9934813

41. Pigazzi A, Heydrich S, Folli F, Benoit S, Michelson A, Loscalzo J. Nitric oxide inhibits thrombin receptor-activating peptide- induced phosphoinositide 3-kinase activity in human platelets. *J. Biol. Chem.* 274(20):14368-75, 1999. PMID: 10318860
42. Svegliati-Baroni GL, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, Macarri G, Perego L, Benedetti A, Folli F. Insulin and insulin-like growth factor- 1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. *Hepatology* 29(6):1743-51, 1999. PMID: 10347117
43. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Cross-talk between insulin and angiotensin II signaling systems. *Exp. Clin. Endocrinol. Diabetes* 107(2):133-9, 1999. PMID: 10320054
44. Alvaro D, Alpini G, Onori P, Perego L, Svegliati Baroni G, Franchitto A, Baiocchi L, Glaser SS, Le Sage G, Folli F, Gaudio E. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. *Gastroenterology* 119(6):1681-91, 2000. PMID: 11113090
45. Meoni C, Bertuzzi F, Pontiroli AE, Falqui L, Monaco L, Soria M, Arcelloni C, Paroni R, Foglieni C, Polastri L, Galbiati F, Folli F, Davalli AM. Development and characterization of pituitary GH3 cell clones stably transfected with a human proinsulin cDNA. *Cell Transplant.* 9(6): 829-40, 2000. PMID: 11202569
46. Davalli AM, Galbiati F, Bertuzzi F, Pontiroli AE, Perego L, Freschi M, Folli F, Meoni C. Insulin-secreting pituitary GH3 cells: a potential beta-cell surrogate for diabetes cell therapy. *Cell Transplant.* 9(6): 841-51, 2000. PMID: 11202570
47. Federici M, Hribal M, Perego L, Ranalli M, Bonini P, Caradonna Z, Perego C, Usellini L, Nano R, Bertuzzi F, Marlier L, Davalli AM, Carandente O, Pontiroli AE, Marchetti P, Melino G, Lauro R, Sesti G, Folli F. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. *Diabetes* 50(6):1290-301, 2001. PMID: 11375329
48. Pellegatta F, Radaelli A, Heltai S, Yan L, Chierchia SL, Folli F. Evidence for the involvement of phosphatidylinositol 3-kinase in fMLP-stimulated neutrophil adhesion to ICAM-1 transfected cells. *J. Cardiovasc. Pharmacol.* 37(6):751-61, 2001. PMID: 11392472
49. Pizzocri P, Koprivec D, Folli F, Vedani P, Marchi M, Paganelli M, Pontiroli AE. Changes of lipid levels and degree of weight loss in morbid obesity. *Obes. Surg.* 11(5):649-50, 2001. PMID: 11594114
50. Chiellini C, Bertacca A, Novelli SE, Görgün CZ, Ciccarone A, Giordano A, Xu H, Soukas A, Costa M, Gandini D, Dimitri R, Perego L, Bottone P, Cecchetti P, Pardini E, Navalesi R, Folli F, Benzi L, Cinti S, Friedman JM, Hotamisligil GS, Maffei M. Obesity modulates the expression of haptoglobin in the white adipose tissue via TNF alpha. *J. Cell. Physiol.* 190(2): 251-8, 2002. PMID: 11807829
51. Ponzoni M, Patriarca C, Vicari A, Arrigoni G, Folli F. Extramedullary myeloid cell tumor/granulocytic sarcoma with predilection for serosal surfaces. *Haematologica* 87(3):ECR09, 2002. PMID: 11869955
52. Perego L, Previtali SC, Nemni R, Longhi R, Carandente O, Saibene A, Sciolla R, Villa A, Gai P, Panzeri C, Dell'Antonio G, Quattrini A, Folli F. Autoantibodies to amphiphysin I and amphiphysin II in a patient with sensory-motor neuropathy. *Eur. Neurol.* 47(4): 196-200, 2002. PMID: 12037431
53. Alvaro D, Onori P, Drudi Metalli V, Svegliati-Baroni G, Folli F, Franchitto A, Alpini G, Gaudio E. (2002). Intracellular pathways mediating estrogen- induced cholangiocyte proliferation in the rat. *Hepatology* 36(2): 297-304. PMID: 12143037
54. Pontiroli AE, Pizzocri L, Librenti MC, Vedani P, Marchi M, Orena C, Cucchi E, Paganelli M, Giacomelli M, Ferla GF, Folli F. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three year study. *J. Clin. Endocrinol. Metab.* 87(8):3555-61, 2002. PMID: 12161474
55. Galbiati F, Polastri L., Gregori S, Freschi M, Casorati M, Cavallaro U, Fiorina P, Bertuzzi F, Zerbi A, Thorens B, Pozza G, Adorini L, Folli F, Christofori G, Davalli A M. Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors. *Endocrinology* 143(10):4018-30, 2002. PMID: 12239113
56. Pontiroli AE, Pizzocri P, Giacomelli M, Marchi M, Vedani P, Cucchi E, Orena C, Folli F, Paganelli M, Ferla G. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding:

- comparison with computerized tomography and with anthropometric measurements. *Obes. Surg.* 12(5): 648-51, 2002. PMID: 12448386
57. Polastri L, Galbiati F, Folli F, Davalli AM. Effects of Carboxypeptidase E overexpression on insulin mRNA Levels, regulated insulin secretion, and proinsulin processing of pituitary GH3 cells transfected with a furin-cleavable human proinsulin cDNA. *Cell Transplant.* 11(8): 803-11, 2002. PMID: 12588113
58. Pontiroli AE, Pizzocri P, Folli F. Plasma leptin levels and coronary heart disease. (*Letter to the Editor*): *Circulation* 106(9):e42, 2002. PMID: 12196352
59. Folli F, Perego L, Ponzoni M, Girardi AM, Bosi E, Ferreri AJM, Bellone M, Sabbadini MG, Vicari AM, Trusolino L. Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjogren's syndrome and gastric MALT lymphoma. *Ann. Hematol.* 81:597-602, 2002. PMID: 12424543
60. Folli F, Piccolo G. The clinical spectrum of stiff-man syndrome: pathogenetic, nosological and therapeutic considerations. In: *Autoantibodies in Neurological Diseases*. A. Vincent, G. Martino, Eds (Springer Verlag). pp: 124-135, 2002.
61. Folli F, Quattrini A, Galardi G. Stiff-man syndrome. In: *Neuromuscular Diseases in Clinical Practice*. Katirij B, Kaminski HJ, Preston DC, Ruff R, Shapiro BE, Eds (Boston, Butterworth Heinemann) pp: 1247-1256, 2002.
62. Alvaro D, Alpini G, Onori P, Franchitto A, Glaser SS, Le Sage G, Folli F, Attili AF, Gaudio E. Alfa and beta estrogen receptor and the biliary tree. *Mol. Cell. Endocrinol.* 193(1-2):105-8, 2002. PMID: 12161009
63. Carvalheira JBC, Ribeiro EB, Folli F, Velloso LA, Saad MJA. Interaction between leptin and insulin signaling pathways differentially affects JAK-STAT and PI 3-kinase-mediated signaling in rat liver. *Biol. Chem.* 384(1): 151-59, 2003. PMID: 12674509
64. Fiorina P, Folli F, Bertuzzi F, Maffi P, Finzi G, Venturini M, Socci C, Davalli AM, Orsenigo E, Monti L, Falqui L, Uccella S, La Rosa S, Usellini L, Properzi G, Di Carlo V, Del Maschio A, Capella C, Secchi A. Long term beneficial effect of islet transplantation on diabetic macro-microangiopathy in type 1 diabetic kidney-transplanted patients. *Diabetes Care* 26(4): 1129-36, 2003. PMID: 12663585
65. Fiorina P, Folli F, Maffi P, Placidi C, Finzi G, Bertuzzi F, Davalli AM, Venturini M, Zerbini G, D'Angelo A, Socci C, Orsenigo E, Aldrighetti L, Properzi G, Ponzoni M, Del Maschio A, Capella C, Di Carlo V, Secchi A. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. *Transplantation* 75(8):1296-301, 2003. PMID: 12717219
66. Hribal M, Perego L, Lovari S, Menghini R, Perego C, Finzi G, Usellini L, Capella C, Guzzi V, Lauro D, Bertuzzi F, Davalli AM, Pozza G, Pontiroli AE, Federici M, Lauro R, Brunetti A, Folli F, Sesti G. Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing and signaling in RIN beta cell line and human islets of Langerhans. *FASEB J* 17(8):1340-2, 2003. PMID: 12738810
67. Fiorina P, Folli F, Zerbini G, Maffi P, Gremizzi C, Di Carlo V, Socci C, Bertuzzi F, Kashgarian M, Secchi A. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. *J. Am. Soc. Nephrol.* 14(8): 2150-8, 2003. PMID: 12874470
68. Svegliati-Baroni G, Ridolfi F, Caradonna Z, Saccomanno S, Trozzi L, Taffetani S, Pizzocri P, Marucci L, Benedetti A, Folli F. Regulation of ERK/JNK/p70S6K in two rat models of liver injury and fibrosis. *J. Hepatol.* 39(4): 528-37, 2003. PMID: 12971962
69. Fiorina P, Corradi D, Pinelli S, Maestri R, Lagrasta C, Buscaglia M, Davalli AM, Folli F, Astorri E. Apoptotic/mytogenic pathways during human heart development. *Int. J. Cardiol.* 96(3):409-17, 2004. PMID: 15301895
70. D'Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, Lauro D, Sbraccia P, Federici M, Paganelli M, Pontiroli AE, Lauro R, Perticone F, Folli F, Sesti G. The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. *Diabetes* 53(7):1905-10, 2004. PMID: 15220218
71. Fiorina P, Folli F, D'Angelo A, Finzi G, Pellegatta F, Guzzi V, Fedeli C, Della Valle P, Usellini L, Placidi C, Bifari F, Belloni D, Ferrero E, Capella C, Secchi A. Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. *Diabetes* 53(9): 2291-300, 2004. PMID: 15331538

72. Veronelli A, Laneri M, Ranieri R, Koprivec D, Vardaro D, Paganelli M, Folli F, Pontiroli AE. White blood cells in obesity-diabetes: effects of weight loss and normalization of glucose metabolism. *Diabetes Care* 27(10): 2501-2, 2004. PMID: 15451926
73. Fiorina P, Folli F, Bifari F, Ventre MB, Finzi G, Mazzolari G, Fedeli C, Guzzi V, Delle Valle P, Placidi C, Belloni D, Ferrero E, Capella C, D'Angelo A, Secchi A. Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. | [Emostasi nei pazienti diabetic e uremici: Impatto del trapianto di rene e pancreas]. *Giornale Italiano di Diabetologia e Metabolismo* 24(2):43-50, 2004.
74. Folli F. Viaggio nella patogenesi del diabete di tipo 2 (diabete non-insulino dipendente). Studi clinici e molecolari. *Il Diabete*, 2005.
75. Lucotti P, Galimberti G, Folli F, Bosi E. Severe insulin-resistant diabetes mellitus in a patient affected by a desmoids tumor of the abdominal wall: A novel paraneoplastic syndrome? | [Diabete gravemente insulin-resistente associate a tumore desmoide della parete addominale]. *Giornale Italiano di Diabetologia e Metabolismo* 25(2):85-88, 2005.
76. Ueno M, Carvalheira JB, Tambascia RC, Bezerra RM, Amaral ME, Carneiro EM, Folli F, Franchini KG, Saad MJ. Regulation of insulin signaling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. *Diabetologia* 48(3):506-18, 2005. PMID: 15692808
77. Fiorina P, Venturini M, Folli F, Losio C, Maffi P, Placidi C, La Rosa S, Orsenigo E, Socci C, Capella C, Del Maschio A, Secchi A. Natural History of kidney graft survival, hypertrophy, and vascular function in end stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet co-transplantation. *Diabetes Care* 28(6):1303-10, 2005. PMID: 15920043
78. Fiorina P., Gremizzi C, Maffi P, Caldara R, Tavano D, Monti L, Socci C, Folli F, Fazio F, Astorri E, Del Maschio A, Secchi A. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. *Diabetes Care* 28(6):1358-65, 2005. PMID: 15920052
79. Perego L, Pizzocri P, Maisano F, Paganelli M, Corradi D, Fiorina P, Barbieri M, Paolisso G, Folli F, Pontiroli AE. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. *J. Clin. Endocrinol. Metab.* 90(7):4087-93, 2005. PMID: 15855267
80. Cardellini M, Perego L, D'Adamo M, Marini MA, Procopio C, Hribal ML, Andreozzi F, Frontoni S, Giacomelli M, Paganelli M, Pontiroli AE, Lauro R, Folli F, Sesti G. . The C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. *Diabetes Care* 28(8):2007-12, 2005. PMID: 16043746
81. Sesti G*, Perego L, Cardellini M, Andreozzi F, Ricasoli C, Vedani P, Guzzi V, Marchi M, Paganelli M, Ferla G, Pontiroli AE, Hribal ML, Folli F* (*Corresponding Authors). Impact of common polymorphisms in candidate genes for insulin resistance and obesity on weight loss of morbidly obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. *J. Clin. Endocrinol. Metab.* 90(9):5064-9, 2005. PMID: 15985484
82. Fiorina P, Folli F, Ferrero E, Orsenigo E, Finzi G, Mazzolari G, Placidi C, Perego L, La Rosa S, Melandri M, Monti L, Capella C, D'Angelo A, Staudacher C, Secchi A. Morphological and functional differences in haemostatic axis between kidney transplanted and end-stage renal disease patients. *Transpl. Int.* 18(9):1036-47, 2005. PMID: 16101724
83. Pontiroli AE, Folli F, Paganelli M, Micheletto G, Pizzocri P, Vedani P, Luisi F, Perego L, Morabito A, Bressani Doldi S. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year controlled study. *Diabetes Care* 28(11):2703-9, 2005. PMID: 16249543
84. Finzi, G, Davalli AM, Placidi C, Usellini L, La Rosa S, Folli F, Capella C. Morphological and ultrastructural features of human islet grafts performed into diabetic nude mice. *Ultrastruct. Pathol.* 29(6):525-33, 2005. PMID: 16316953
85. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical

- Trial In macroVascular Events): a randomised controlled trial. *Lancet*. 2005 Oct 8;366(9493):1279-89.
86. Scavini M, Pontiroli A, Folli F. Asymptomatic hyperinsulinemic hypoglycemia after gastric banding. (Letter to the Editor). *New Engl. J. Med.* 353(26):2822-3, 2005. PMID: 16382076
 87. Folli F, Galimberti G, Pastore M, Davalli AM, Bosi E. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate. *Diabetes Care* 29(9):2178-80, 2006. PMID: 16936177
 88. Velloso L, Folli F, Perego L, Saad MJA. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. *Diabetes Metab Res Rev* 22(2):98-107, 2006. PMID: 16389635
 89. Folli F, Sommer C . Stiff-person syndrome. Atlas Genet Cytogenet Oncol Haematol December 2006 .URL : <http://AtlasGeneticsOncology.org/Kprones/StiffpersonID10103.html>
 90. Pontiroli AE, Pizzocri P, Paroni R, Folli F. Sympathetic overactivity, endothelial dysfunction, inflammation, and metabolic abnormalities cluster in grade III (World Health Organization) obesity: reversal through sustained weight loss obtained with laparoscopic adjustable gastric banding (LAGB). *Diabetes Care* 29(12): 2735-8, 2006. PMID: 17130217
 91. Perani D, Garibotto V, Moresco RM, Ortelli P, Corbo M, Fazio F, Folli F. PET evidence of central GABAergic changes in stiff-person syndrome *Mov. Disord.* 22(7):1030-3, 2007. PMID: 17575583
 92. Prudente S, Flex E, Morini E, Turchi F, Capponi D, De Cosmo S, Tassi V, Guida V, Avogaro A, Folli F, Maiani F, Frittitta L, Dallapiccola B, Trischitta V. A functional variant of the adipocyte glycerol channel aquaporin 7 gene is associated with obesity and related metabolic abnormalities. *Diabetes* 56(5):1468-74, 2007. PMID: 17351148
 93. Pontiroli AE, Fossati A, Vedani P, Fiorilli M, Folli F, Paganelli M, Marchi M, Maffei C. Post-surgery adherence to scheduled visits and compliance more than personality disorders, predict outcome of bariatric restrictive surgery in morbidly obese patients. *Obes. Surg.* 17(11):1492-7, 2007. PMID: 18219777
 94. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. *J Am Coll Cardiol.* 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.
 95. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). *Diabetes Care.* 2007 Nov;30(11):2773-8. Epub 2007 Jul 31.
 96. Folli F, Pontiroli AE, Schwesinger WH. Metabolic aspects of bariatric surgery. *Med Clin North Am* 91(3):393-414, 2007. PMID: 17509385
 97. Muscogiuri G, Chavez AO, Gastaldelli A, Perego L, Tripathy D, Saad MJ, Velloso L, Folli F. The crosstalk between insulin and renin-angiotensin-aldosterone signalling systems and its effect on glucose metabolism and diabetes prevention. *Curr. Vasc. Pharmacol.* 6(4):301-12, 2008. PMID: 18855718
 98. Chavez AO, Lopez-Alvarenga JC, Tejero ME, Triplitt C, Bastarrachea RA, Sriwijitkamol A, Tantiwong P, Voruganti VS, Musi N, Comuzzie AG, DeFronzo RA, Folli F. Physiological and molecular determinants of insulin action in the baboon. *Diabetes* 57(4):899-908, 2008. PMID: 18174524
 99. Coletta DK, Balas B, Chavez AO, Baig M, Abdul-Ghani M, Kashyap SR, Folli F, Tripathy D, Mandarino LJ, Cornell JE, DeFronzo RA, Jenkinson CP. Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo. *Am. J. Physiol. Endocrinol. Metab.* 294(4):E910-7, 2008. PMID: 18334611
 100. Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zou P, Chang Z, Tripathy D, Jani R, Molina-Carrion M, Monroy A, Folli F, Van Remmen H, DeFronzo RA. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. *Am. J. Physiol. Endocrinol. Metab.* 295(3):E678-85, 2008. PMID: 18593850

101. Pontiroli AE, Frigè F, Paganelli M, Folli F. In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: effect of weight loss through surgery. *Obes. Surg.* 19(6):745-50, 2008. PMID: 18629594
102. Davalli AM, Perego L, Bertuzzi F, Finzi G, La Rosa S, Blau A, Placidi C, Nano R, Gregorini L, Perego C, Capella C, Folli F. Disproportionate hyperproinsulinemia, beta-cell restricted prohormone convertase 2 deficiency and cell cycle inhibitors expression by human islets transplanted into athymic nude mice: insights into nonimmune-mediated mechanisms of delayed islet graft failure. *Cell Transplant.* 17(12):1323-36, 2008. PMID: 19364070
103. Gastaldelli A, Perego L, Paganelli M, Sesti G, Hribal M, Chavez AO, RA DeFronzo, Pontiroli A, Folli F. Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding. *Obes. Surg.* 19(1):80-6, 2009. PMID: 18820980
104. Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V, Tornei F, Bertucci P, Iacobini C, Serino M, Porzio O, Hribal ML, Folli F, Khokha R, Urbani A, Lauro R, Pugliese G, Federici M. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. *Gastroenterology* 136(2):663-72, 2009. PMID: 19027012
105. Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, DeFronzo RA, Tripathy D. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. *Am. J. Physiol. Endocrinol. Metab.* 296(4):E758-64, 2009. PMID: 19190263
106. Dall'Asta C, Vedani P, Manunta P, Pizzocri P, Marchi M, Paganelli M, Folli F, Pontiroli AE. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. *Nutr. Metab. Cardiovasc. Dis.* 19(2):110-4, 2009. PMID: 18718746
107. Frigè F, Laneri M, Veronelli A, Folli F, Paganelli M, Vedani P, Marchi M, Noé D, Ventura P, Opocher E, Pontiroli AE. Bariatric surgery in obesity: changes of glucose and lipid metabolism correlate with changes of fat mass. *Nutr. Metab. Cardiovasc. Dis.* 19(3):198-204, 2008. PMID: 18684601
108. Pontiroli A.E., Frige F., Paganelli M., Folli F. In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: Effect of weight loss through surgery. *Obes. Surg.* 19(6):745-50, 2009. PMID: 18629594
109. Chavez AO, Gastaldelli A, Guardado-Mendoza R, Lopez Alvarenga JC, Leland MM, Tejero ME, Sorice G, Casiraghi F, Davalli AM, Bastarrachea RA, Comuzzie AG, DeFronzo RA, Folli F. Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons. *Cardiovasc. Diabetol.* 8:22, 2009. PMID: 19389241
110. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating Fibroblast Growth Factor-21 (FGF-21) is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. *Diabetes Care* 32 (8):1542-1546, 2009. PMID: 19487637
111. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, Wewer JJ, Coletta DK, Jenkinson C, Jhingan RM, Smokler D, Reyna S, Musi N, Khokka R, Federici M, Tripathy D, DeFronzo RA, Folli F. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. *Diabetologia* 52(10):2169-2181, 2009. PMID: 19633828
112. Guardado-Mendoza R, Dick EJ Jr, Jimenez-Ceja LM, Davalli A, Chavez AO, Folli F, Hubbard GB. Spontaneous pathology of the baboon endocrine system. *J. Med. Primatol.* 38(6):383-389, 2009. PMID: 19793179
113. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Goldschmidt L, Hart J, Perego C, Comuzzie AG, Tejero ME, Finzi G, Placidi C, La Rosa S, Capella C, Halff G, Gastaldelli A, DeFronzo RA, Folli F. Pancreatic Islet Amyloidosis, Beta Cell Apoptosis and Alpha Cell Proliferation are Determinants of Islet Remodeling in Type 2 diabetic baboons. *Proc. Natl. Acad. Sci. USA* 106(33):13992-7, 2009. PMID: 19666551

114. Sorice GP, Folli F. A combination of PPAR γ Agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (Aortic Aneurysm Syndromes). *Med. Hypotheses* 73(4):614-618, 2009. PMID: 19577852
115. Dall'Asta C, Paganelli M, Morabito A, Vedani P, Barbieri M, Paolisso G, Folli F, Pontiroli AE. Weight loss through gastric banding: effect on TSH and thyroid hormones in obese subject with normal thyroid function. *Obesity* 18(4):854-7, 2010. PMID: 19834461
116. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, Porzio O, Mauriello A, Solini A, Ippoliti A, Lauro R, Folli F, Federici M. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by Sirt1. *Diabetes* 58(10):2396-2401, 2009. PMID: 19581416
117. Pontiroli AE, Laneri M, Veronelli A, Frige' F, Micheletto G, Folli F, Adami G, Scopinaro N. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and cardiovascular parameters. *Cardiovasc. Diabetol.* 8(1):37, 2009. PMID: 19619292
118. Chavez AO, Kamath S, Jani R, Sharma LK, Monroy A, Abdul-Ghani MA, Centonze VE, Sathyanarayana P, Coletta DK, Jenkinson CP, Bai Y, Folli F, DeFronzo RA, Tripathy D. Effect of short-term free Fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals. *J. Clin. Endocrinol. Metab.* 95(1):422-429, 2010. PMID: 19864449
119. Folli F, Guzzi V, Perego L, Coletta DK, Finzi G, Placidi C, La Rosa S, Capella C, Soggi C, Lauro D, Tripathy D, Jenkinson C, Paroni R, Orsenigo E, Cighetti G, Gregorini L, Staudacher C, Secchi A, Bachi A, Brownlee M, Fiorina P. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. *PLoS One* 29;5(3):e9923, 2010. PMID: 20360867
120. Charbonnel B, DeFronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V, Scheen A; PROactive investigators. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). *J Clin Endocrinol Metab.* 2010 May;95(5):2163-71. doi: 10.1210/jc.2009-1974. Epub 2010 Mar 17.
121. Gastaldelli A, Folli F, Maffei S. Impact of tobacco smoking on lipid metabolism, body weight and cardiometabolic risk. *Curr. Pharm. Des.* 16(23):2526-30, 2010. PMID: 20550509
122. Di Cairano ES, Davalli AM, Perego L, Sala S, Franca Sacchi VF, La Rosa S, Placidi C, Capella C, Conti P, Centonze VE, Casiraghi F, Bertuzzi F, Folli F, Perego C. The Glial Glutamate Transporter 1 (GLT1) is expressed by pancreatic β -cells and prevents glutamate-induced β -cell death. *J. Biol. Chem.* 286(16):14007-18, 2011. PMID: 21335552
123. Geis C, Weishaupt A, Grünwald B, Wultsch T, Reif A, Gerlach M, Dirx R, Solimena M, Perani D, Heckmann M, Toyka KV, Folli F, Sommer C. Human stiff-person syndrome IgG induces anxious behavior in rats. *PLoS One* 6(2):e16775, 2011. PMID: 21346811
124. Davalli AM, Perego C, Folli F, Bosi E. Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. A Case Report. *Acta Diabetol.* 2011 Feb 19. [Epub ahead of print]. PMID: 21336872
125. Sesti G, Folli F, Perego L, Hribal ML, Pontiroli AE. Effects of weight loss in metabolically healthy subjects after laparoscopic adjustable gastric banding and hypocaloric diet. *PLoS One.* 6(3):e17737, 2011. PMID: 21408112
126. Andreozzi F, Procopio C, Greco A, Mannino GC, Miele C, Raciti GA, Iadicicco C, Beguinot F, Pontiroli AE, Hribal ML, Folli F, Sesti G. Increased levels of the Akt specific phosphatase PH domain leucine rich repeat protein phosphatase 1 (PHLPP1) in obese subjects is associated with insulin resistance. *Diabetologia* 54(7):1979-87, 2011. PMID: 21461637
127. Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study. *Diabet Med* 28(10):1206-12, 2011. PMID: 21388447
128. Kamath S, Chavez AO, Gastaldelli A, Casiraghi F, Halff GA, Abrahamian GA, Davalli AM, Bastarrachea RA, Comuzzie AG, Guardado-Mendoza R, Jimenez-Ceja LM, Mattern V, Paez AM, Ricotti A, Tejero ME, Higgins PB, Rodriguez-Sanchez IP, Tripathy D, DeFronzo RA, Dick EJ Jr, Cline GW, Folli F. Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non human primates. *PLoS One* 6(11):e27617, 2011. PMID: 22125617
129. Folli F, Okada T, Perego C, Gunton J, Liew CW, Akiyama M, D'Amico A, La Rosa S,

- Placidi C, Lupi R, Marchetti P, Sesti G, Hellerstein M, Perego L, Kulkarni RN. Altered insulin receptor signalling and β -cell cycle dynamics in type 2 diabetes mellitus. *PLoS One* 6(11):e28050, 2011. PMID: 22140505
130. Muscogiuri G, Sorice GP, Tripathy D, Chavez AO, Davalli A, Lange RA, Folli F. Medical therapy of aortic aneurysms a pathophysiology-based approach. *Curr. Vasc. Pharmacol.* 9(5):572-84, 2011. PMID: 21143163
 131. Folli F, Guardado Mendoza R. Potential use of exenatide for the treatment of obesity. *Expert Opin. Investig. Drugs* 20(12):1717-22, 2011. PMID: 22017240
 132. Sironi AM, Sicari R, Folli F, Gastaldelli A. Ectopic fat storage, insulin resistance, and hypertension. *Curr. Pharm. Des.* 17(28):3074-80, 2011. PMID: 21861830
 133. Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. *Curr. Diabetes Rev.* 7(5):313-24, 2011 PMID: 21838680
 134. Westermarck GT, Davalli AM, Secchi A, Folli F, Kin T, Toso C, Shapiro AM, Korsgren O, Tufveson G, Andersson A, Westermarck P. Further Evidence for Amyloid Deposition in Clinical Pancreatic Islet Grafts. *Transplantation* 93(2):219-223, 2012. PMID: 22193043.
 135. Quinn AR, Blanco CL, Perego C, Finzi G, La Rosa S, Capella C, Guardado-Mendoza R, Casiraghi F, Gastaldelli A, Johnson M, Dick EJ, Folli F. The Ontogeny of the Endocrine Pancreas in the Fetal/Newborn Baboon. *Journal of Endocrinology*, 2012
 136. Casiraghi F, Chavez AO, Musi N, Folli F. The baboon as a primate model to study the physiology and metabolic effects of exercise. In: *Cellular Physiology and Metabolism of Physical Exercise*. Luzi L. Ed.(Springer Verlag). pp: 147-161, 2012.
 137. Davalli AM, Perego C, Folli F. The potential role of glutamate in the current diabetes epidemic. *Acta Diabetol.* 2012 Jun;49(3):167-83. PMID:22218826
 138. Folli F, Sabowitz BN, Schwessinger W., Fanti P., Guardado-Mendoza R., Muscogiuri G. Bariatric surgery and bone disease: from clinical perspective to molecular insights. *Int J Obes (Lond)*. 2012 Nov;36(11):1373-9. PMID: 22828943 Sep;214(3):289-299. Epub 2012 Jun 21. PMID:22723715.
 139. Guardado-Mendoza R, Jimenez-Ceja LM, Majluf-Cruz A, DeFronzo RA, Folli F. Impact of obesity duration and severity on beta and alpha cell mass in normoglycemic non-human primates *Int J. Obes (Lond)*. 2013 Aug;37(8):1071-8. PMID:2322973
 140. Khazim K, D. Giustarini, R. Rossi, D. Verkaik, S. Cunningham, M. Mohammed, K. Trochta, C. Lorenzo, F. Folli, S. Bansal, P. Fanti. Glutathione Redox Potential is Low and Glutathionylated and Cysteinylylated Hemoglobin are High in Maintenance Hemodialysis Patients; Association with Routine Parameters of Dietary Intake. *Transl Res.* 2013 Jul;162(1):16-25. PMID:23333585
 141. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, DeFronzo RA, Folli F. Pioglitazone Improves Glucose Metabolism and Modulates Skeletal Muscle TIMP-3/TACE Dyad in Type 2 Diabetes Mellitus. A randomised double blind-placebo controlled mechanistic study. 2013. *Diabetologia* Oct;56(10):2153-63. PMID:23811853
 142. F. Andreozzi, A. Gastaldelli, GC Mannino, A. Sciacqua, E. Succurro, F. Arturi, F. Folli, F. Perticone. Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction. 2013. *Atherosclerosis* 2013 Aug;229(2):277-81. doi: 10.1016/j.atherosclerosis.2013.05.028. Epub 2013 Jun 6. PMID:23880176
 143. Casiraghi F, Lertwattanarak R, Luzi L, Chavez AO, Davalli AM, Comuzzie A, Frost P, Musi N, Folli F. Energy Expenditure Evaluation in Humans and Non-Human Primates by SenseWear Armband. Validation of the SenseWear Armband by direct comparison with Indirect Calorimetry. 2013. *PLoS One*. 2013 Sep 19;8(9):e73651. PMID:24069218
 144. Del Turco S, Gaggini M, Daniele G, Basta G, Folli F, Sicari R, Gastaldelli A. Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk *Curr Pharm Des.* 2013;19(13):2420-31. PMID:23173591
 145. Fiorentino TV, Prioletta AM, Zuo P, Folli F. Hyperglycemia-induced Oxidative stress and its Role in Diabetes Mellitus related Cardiovascular Diseases. 2013 *Curr Pharm Des.* 2013;19(32):5695-703. PMID:23448484
 146. Folli F., Prioletta AM, Quattrini A, Galardi G. Stiff Man Syndrome, In *Neuromuscular Disorders in Clinical Practice*. Katirji, Kaminski, & Ruff's Editors. (Springer Verlag). 2013.

147. Urbani A., De Canio M., Palmieri F, Sechi S, Bini L, Castagnola M, Fasano M, Modesti A, Roncada P, Timperio AM, Bonizzi L, Brunori M, Cutruzzola' F, De Pinto V, Di Ilio C, Federici G, Folli F, Foti S, Gelfi C, Lauro D, Lucacchini A, Magni F, Messina I, Pandolfi PP, Papa S, Pucci P, Sacchetta P and the Italian mt-HPP Study Group – Italian Proteomics Association (www.itpa.it). *Mol Biosyst.* 2013 Aug;9(8):1984-92. PMID:23712443
148. Guardado-Mendoza R., Prioletta AM, Jiménez-Ceja LM, Sosale A, Folli F. The Role of nateglinide and repaglinide. derivatives of meglitinide in the treatment of type 2 diabetes mellitus. *Arch Med Sci.* 2013;9(5):936-43. PMID:24273582.
149. D'Addio F, Maffi P, Vezzulli P, Bertuzzi F, Vergani A, Mello A, Nano R, Falautano M, Coppi E, Finzi G, Larosa S, Magnani G, Falini A, Folli F, Secchi, Fiorina P. Islet transplantation stabilizes hemostatic abnormalities and cerebral morphology/metabolism in type I diabetic patients. 2014. *Diabetes Care.* 2014 ;37(1):267-76. PMID:24026546.
150. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, Andreozzi F, Jenkinson C, Cersosimo E, Federici M, Tripathy D, Folli F. The inflammatory status score including IL-6, TNF- α , osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. *Acta Diabetol.* 2014;51(1):123-31. PMID: 24370923
151. Cardillo C, Folli F. Obituary of Giuseppe Folli MD, 14/3/1924 – 10/4/2014. 2014 *Journal of Hypertension* 32 (9):1913-1914,
152. Fiorentino TV, Owston M, Abrahamian G, La Rosa S, Marando A, Finzi G, Capella C, Kamath S, Casiraghi F, Comuzzie A, Sharp M, Williams P, DeFronzo RA, Halff G, Dick E, Folli F. Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation or Ductal Hyperplasia in Non-human Primates (Baboons; Papio Amadryas). 2015 *Am J Pathol.* 2015;185(1):139-50.PMID: 25447052
153. Velloso L, Folli F, Saad MJA. 2015. TLR4 at the crossroads of nutrients, gut microbiota and metabolic inflammation. 2015 *Endocrine Reviews.* 36(3):245-71. PMID:25811237
154. F Folli, G. Daniele, S. Werner, S. Kamath, J. Velez Munera, H. Abboud, P. Fanti Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus 2015. *Acta Diabetologica.* 52(5):897-903 PMID: 25753172
155. LOS Leiria, FM. Arantes-Costa, R Moura, MC Calixto, F Folli, CM Prado, MA Prado, VF Prado, LA Velloso, J Donato Jr., E Antunes, MA Martins, MJA Saad. Central hyperinsulinemia increases airway reactivity through the activation of ERK in cholinergic neurons. 2015 *Cell Reports* 11(6):934-43. PMID:25937275
156. R Guardado-Mendoza, C Perego, G Finzi, S. La Rosa, C Capella, LM Jimenez-Ceja, LA Velloso, MJA Saad, F Sessa, F Bertuzzi, S Moretti, EJ Dick Jr, AM Davalli, F Folli. δ -cells death in the islets of Langerhans and the progression from normal glucose tolerance to type 2 diabetes mellitus in non-human primates (Baboon, Papio Hamadryas). 2015 *Diabetologia* 58(8):1814-26. PMID: 26049399
157. Daniele G., Winnier D, Mari A, Bruder J, Fourcadot M, Pengou Z, Tripathy D, Jenkinson G, Folli F. Sclerostin and Insulin Resistance In Prediabetes. Evidence Of a Cross-Talk Between Bone and Glucose Metabolism. 2015 *Diabetes Care* 38(8):1509-17. PMID: 26084344
158. B Rachid, S van de Sande-Lee, S Rodovalho, F Folli, GC Beltramini, J Morari, BJ Amorim, T Pedro, AJ Tincani, E Chaim, JC Pareja, B Geloneze, CD Ramos, F Cendes, MJASaad, LA Velloso Distinct regulation of hypothalamic and brown/beige adipose tissue activities in human obesity. 2015 *Int J Obes (London)* 39(10):1515-22. PMID: 25994805
159. Fanti P, Giustarini D, Rossi R, Folli F, Khazim K, Hirachan P, Cunningham S, Gross G, Bansal S. Plasma Cyst(e)ine Levels and Protein Thiolation Index Associate with Dietary Protein and Calorie Intake in End-Stage Renal Disease. 2015 (*Journal of Renal Nutrition* 25(6):494-503. PMID: 26235932
160. P. Ouaresma, N. Reencober, T. Zanutto, A. Santos, L. Weissmann, A. Berenguer de Matos, I. Lopes-Cendes, F. Folli, MJA Saad, P. O Prada. Pioglitazone Treatment Increases Food Intake and Decreases Energy Expenditure Partially Via Hypothalamic Adiponectin/AdipoR1/AMPK Pathway. 2016. *Int J Obes (Lond)* 40(1):138-46 PMID:26228462
161. F D'Addio, S La Rosa, A Maestroni, E Orsenigo, M Ben Nasr, S Tezza, R Bassi, G Finzi, A Marando, R Frego, L Albarello, R Manguerra, D Corradi, E Viale, P Jung, C Staudacher, D Breult, A Secchi, F Folli, P. Fiorina. 2015. Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy. *Cell Stem Cell* 17(4):486-98. PMID: 26431183

162. Di Cairano ES, Moretti S, Sacchi VF, Castagna M, Marciani P, Davalli AM, Folli F, Perego C. Neurotransmitters and neuropeptides in the in the endocrine pancreas: an opportunity for intervention in diabetes. 2015. *Journal of Physiology* Aug 31. doi: 10.1002/jcp.25176. [Epub ahead of print] PMID:26332080
163. Androozzi F, Raciti GA, Nigro C, Mannino GC, Procopio T, Davalli AM, Beguinot F., Sesti G, Miele C, Folli F. The GLP-1 Receptor Agonists Exenatide and Liraglutide Activates Glucose Transport by an AMPK-Dependent Mechanism. 2016 *Journal of Translational Medicine* Jul 30;14(1):229. doi: 10.1186/s12967-016-0985-7. PMID: 27473212
164. Higgins PB, Shade RE, Forey M, Rodriguez-Sanchez PI, Comuzzie AG, Folli F. Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates, (Baboons; Papio Amadryas). 2016 *Am. J Physiol.* Oct 1;311(4):E661-E670. doi:10.1152/ajpendo.00166.2016. PMID:27530231
165. Guardado-Mendoza R, Chávez AO, Jiménez-Ceja L, DeFronzo RA, Folli F, Tripathy D. Dynamic changes in amylin secretion in response to glucose and arginine in normal glucose tolerant, impaired glucose tolerant and type 2 diabetic patients. 2017. *Acta Diabetologica* Jan;54(1):53-61.. PMID:27624579
166. Patti ME, Goldfine A, Hu J, Hoern D, Molven A, Goldsmith J, Schwessinger W, Folli F, Kulkarni RN. Alterations in the proliferation of pancreatic cells in patients with Severe Hypoglycemia following Roux-en-Y Gastric Bypass. 2017. *Acta Diabetologica* Aug;54(8):737-747. PMID:28512677
167. S. Rodovalho, B. Rachid, J.C. De Lima-Júnior, S. van de Sande-Lee, J. Morari, H. Carvalho, B. Amorim, A. Tincani, E. Chaim, J. Pareja, M. Saad, F. Folli, C. Ramos, B. Geloneze, and L. Velloso Impairment of body mass reduction-associated activation of brown/beige adipose tissue in patients with type 2 diabetes mellitus. 2017 *Int J. Obes (London)* Jul 3. doi: 10.1038/ijo.2017.152. [Epub ahead of print] PMID: 28669988
168. SG Garbossa, F. Folli. Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism. 2017. *Reviews in Endocrine and Metabolic Disorders* Jun;18(2):243-258. doi: 10.1007/s11154-017-9423-2. PMID: 2840932
169. Pontiroli AE, Ceriani V, Folli F. Patients' Expectations are Important for Success in Bariatric Surgery. *Obes Surg.* 2017 Jul 1. doi: 10.1007/s11695-017-2788-1. [Epub ahead of print]. PMID: 28669070.
170. Daniele G, Winnier D, Mari A, Bruder J, Fourcadot M, Zuo P, Tripathy D, Jenkinson C, Folli F. The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans. 2018. *Acta Diabetol.* 2018 Nov 18. doi: 10.1007/s00592-017-1065-z. [Epub ahead of print]. PMID: 29151224
171. Pontiroli AE, Ceriani V, Folli F. More on Patients Expectations and Success with Bariatric Surgery. *Obes Surg.* 2018 Feb 1. doi: 10.1007/s11695-018-3127-x. [Epub ahead of print] No abstract available. PMID:29392630
172. S.Piro, F. Urbano, F. Folli, G. Finzi, L. Marselli, P. Marchetti. The Endocrine Pancreas 16. 2018 *Principles of Endocrinology and Hormone Action*. Springer International Publishing
173. Pace F, Carvalho BM, Zanotto TM, Santos A, Guadagnini D, Silva KLC, Mendes MCS, Rocha GZ, Alegretti SM, Santos GA, Catharino RR, Paroni R, Folli F, Saad MJA. Helminth infection in mice improves insulin sensitivity via modulation of gut microbiota and fatty acid metabolism. *Pharmacol Res.* 2018 Jun;132:33-46. PMID: 29653264.
174. Pontiroli AE, Osio C, Ceriani V, Folli F. Advanced Age and Success of Bariatric Surgery. *Obes Surg.* 2018 Jul;28(7):2053. PMID: 29675637.
175. D'Addio F, Vergani A, Potena L, Maestroni A, Uselli V, Ben Nasr M, Bassi R, Tezza S, Dellepiane S, El Essawy B, Iascone M, Iacovoni A, Borgese L, Liu K, Visner G, Dhe-Paganon S, Corradi D, Abdi R, Starling RC, Folli F, Zuccotti GV, Sayegh MH, Heeger PS, Chandraker A, Grigioni F, Fiorina P. P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. *J Clin Invest.* 2018 Aug 1;128(8):3490-3503. PMID: 30010623
176. Li X, Rensing C, Taylor WL, Costelle C, Brejnrod AD, Ferry RJ Jr, Higgins PB, Folli F, Kottapalli KR, Hubbard GB, Dick EJ Jr, Yooseph S, Nelson KE, Schlabritz-Loutsevitch N. Papio spp. Colon microbiome and its link to obesity in pregnancy. *J Med Primatol.* 2018 Dec;47(6):393-401. PMID: 30039863

177. Tezza S, Ben Nasr M, D'Addio F, Vergani A, Usuelli V, Falzoni S, Bassi R, Dellepiane S, Fotino C, Rossi C, Maestroni A, Solini A, Corradi D, Giani E, Mameli C, Bertuzzi F, Pezzolesi MG, Wasserfall CH, Atkinson MA, Füchtbauer EM, Ricordi C, Folli F, Di Virgilio F, Pileggi A, Dhe-Paganon S, Zuccotti GV, Fiorina P. Islet-Derived eATP Fuels Autoreactive CD8(+) T Cells and Facilitates the Onset of Type 1 Diabetes. *Diabetes*. 2018 Oct;67(10):2038-2053. PMID: 30065030.
178. Mezza T, Ferraro PM, Sun VA, Moffa S, Cefalo CMA, Quero G, Cinti F, Sorice GP, Pontecorvi A, Folli F, Mari A, Alfieri S, Giaccari A. Increased β -Cell Workload Modulates Proinsulin-to-Insulin Ratio in Humans. *Diabetes*. 2018 Nov;67(11):2389-2396. PMID:30131390.
179. Folli F, La Rosa S, Finzi G, Davalli AM, Galli A, Dick EJ Jr, Perego C, Mendoza RG. Pancreatic islet of Langerhans' cytoarchitecture and ultrastructure in normal glucose tolerance and in type 2 diabetes mellitus. *Diabetes Obes Metab*. 2018 Sep;20 Suppl 2:137-144.. Review. Erratum in: *Diabetes Obes Metab*. 2018 Dec;20(12):2925. PubMed PMID: 30230173.
180. Bifari F, Manfrini R, Dei Cas M, Berra C, Siano M, Zuin M, Paroni R, Folli F. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). *Pharmacol Res*. 2018 Nov;137:219-229. PMID: 30359962.
181. Pontiroli AE, Zakaria AS, Fanchini M, Osio C, Tagliabue E, Micheletto G, Saibene A, Folli F. A 23-year study of mortality and development of co-morbidities in patients with obesity undergoing bariatric surgery (laparoscopic gastric banding) in comparison with medical treatment of obesity. *Cardiovasc Diabetol*. 2018 Dec 29;17(1):161. doi: 10.1186/s12933-018-0801-1. PMID: 30594184.
182. Pontiroli AE, Ceriani V, Sarro G, Micheletto G, Giovanelli A, Zakaria AS, Fanchini M, Osio C, Nosari I, Veronelli AM, Folli F; LAGB10 working group. Incidence of Diabetes Mellitus, Cardiovascular Diseases, and Cancer in Patients Undergoing Malabsorptive Surgery (Biliopancreatic Diversion and Biliointestinal Bypass) vs Medical Treatment. *Obes Surg*. 2019 Mar;29(3):935-942. doi: 10.1007/s11695-018-3601-5 PMID: 30448983.
183. Folli F, Secchi A, La Rocca E, Bosi E, Pontiroli AE. Guido Pozza M.D.: a visionary scholar. *Acta Diabetol*. 2019 Jan;56(1):3-5. PMID: 30569237
184. Pontiroli AE, Zakaria AS, Micheletto G, Osio C, Saibene A, Folli F; LAGB10 Group. A 9 years comparison of weight loss, disappearance of obesity, and resolution of diabetes mellitus with biliointestinal bypass and with adjustable gastric banding: experience of a collaborative network. *Acta Diabetol*. 2019 Feb;56(2):163-169. PMID: 30411157.
185. Higgins PB, Folli F, Andrade MCR, Foster J, Mattern V, Paroni R, Schlabritz-Loutsevitch N, Voruganti VS, Kumar S, Guardado-Mendoza R, Bulfamante G, Fiorina P, Pontiroli AE, Hubbard GB, Owston M, Dick EJ Jr, Comuzzie AG. Duodenal adipose tissue is associated with obesity in baboons (*Papio sp*): a novel site of ectopic fat deposition in non-human primates. *Acta Diabetol*. 2019 Feb;56(2):227-236. PMID: 30673859
186. Berra C, De Fazio F, Azzolini E, Albin M, Zangrandi F, Mirani M, rodolfo Guardado-Mendoza R, Condorelli G, Folli F. . 2019. Hypoglycemia, Hyperglycemia and glucose variability are risk factors for falls in the hospital setting. *Acta Diabetol*. 2019 Mar 30. doi: 10.1007/s00592-019-01323-8. [Epub ahead of print] PMID:3092907
187. Mancini M, Carrafiello G, Melchiorre F, Pelliccione F, Andreassi A, Mantellassi G, Zakaria AS, Pecori Giraldi F, Banderali G, Folli F. 2019. Early varicocelelectomy by percutaneous sclera-embolization improves seminiferous tubules spermatozoa maturation and release in the adolescent phase of testicular growth *Andrologia*. 2019 Apr 14:e13286. doi: 10.1111/and.13286. [Epub ahead of print] PMID:3098302
188. Vilchis-Flores LH, Barajas-Medina GA, Villa-Martínez AK, Salazar López SS, Luna-Patiño GA, Quiroz-Hernández ME, Guzmán-Vanegas MA, Rodríguez-Cortes R, Angulo-Romero F, Reyes-Escogido ML, Aguilar-García A, Jiménez-Ceja LM, Folli F, Guardado-Mendoza R. Pancreatic β -cell dysfunction in normoglycemic patients and risk factors. *Acta Diabetol*. 2019 Aug 29. doi: 10.1007/s00592-019-01411-9. [Epub ahead of print] PMID: 31468201

189. Berra CC, De Fazio F, Azzolini E, Albin M, Zangrandi F, Mirani M, Garbossa S, Guardado-Mendoza R, Condorelli G, Folli F. Reply to letter to the editor by Bonaventura et al. *Acta Diabetol*. 2019 Jun 24. doi: 10.1007/s00592-019-01380-z. [Epub ahead of print] No abstract available. PMID: 31236673
190. Vilchis-Flores LH, Barajas-Medina GA, Villa-Martínez AK, Salazar López SS, Luna-Patiño GA, Quiroz-Hernández ME, Guzmán-Vanegas MA, Rodríguez-Cortés R, Angulo-Romero F, Reyes-Escogido ML, Aguilar-García A, Jiménez-Ceja LM, Folli F, Guardado-Mendoza R. Pancreatic β -cell dysfunction in normoglycemic patients and risk factors. *Acta Diabetol*. 2019 Aug 29. doi: 10.1007/s00592-019-01411-9. [Epub ahead of print] PMID:3146820
191. JC. de-Lima-Júnior; S Rodovalho; S Van de Sande-Lee; M Monfort-Pires; B Rachid; RM. Cintra; CD. Ramos; F Cendes; F. Folli; L.A Velloso. Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus – a proof-of-concept study. 2019. *Acta Diabetologica* , in press.
192. Fiorentino TV*, Casiraghi F*, Davalli AM*, Finzi G, La Rosa S, Higgins PB, Abrahamian GA, Marando A, Sessa F, Perego C, Guardado-Mendoza R, Kamath S, Ricotti A, Fiorina P, Daniele G, Paez AM, Andreozzi F, Caumo A, Bastarrachea RA, Comuzzie A, Gastaldelli A, Chavez AO, Di Cairano ES, Frost P, Luzi L, DickeJr., Halff GA, DeFronzo RA, Folli F. "Exenatide regulates pancreatic islet integrity and insulin sensitivity in baboons" (* Contributed equally/First Authors) – (*JCI Insights* –2019 Oct 17;4(20):e93091. doi: 10.1172/jci.insight.93091.PMID: 31536476
193. Pontiroli AE, Ceriani V, Tagliabue E, Zakaria AS, Veronelli A, Folli F, Zanoni I Bariatric surgery, compared to medical treatment, reduces morbidity at all ages but does not reduce mortality in patients aged < 43 years, especially if diabetes mellitus is present: a post hoc analysis of two retrospective cohort studies. *Acta Diabetol*. 2020 Mar;57(3):323-333. doi: 10.1007/s00592-019-01433-3. Epub 2019 Oct 9. PMID: 31598798
194. R. Guardado-Mendoza, SS Salazar-López, MF de la Luz Álvarez-Canales, D Farfán Vázquez, Y Estrella Martínez-López, LM. Jiménez-Ceja, EL. Suárez-Pérez, F Angulo-Romero, ML Evia-Viscarra , ML Montes de Oca-Loyola , EG. Durán-Pérez MD , F. Folli , A. Aguilar-García. 2019 The combination of Linagliptin, metformin and lifestyle modification to prevent type 2 diabetes: A randomized clinical trial (PRELLIM). *Metabolism*. 2020 Mar;104:154054. doi:10.1016/j.metabol.2019.154054. Epub 2019 Dec 28. PMID: 31887309
195. Solerte SB, D'Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, Dell'Acqua M, Ippolito E, Scaranna C, Bellante R, Galliani S, Dodesini AR, Lepore G, Geni F, Fiorina RM, Catena E, Corsico A, Colombo R, Mirani M, De Riva C, Oleandri SE, Abdi R, Bonventre JV, Rusconi S, Folli F, Di Sabatino A, Zuccotti G, Galli M, Fiorina P. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. *Diabetes Care*. 2020 Dec;43(12):2999-3006. doi: 10.2337/dc20-1521. Epub 2020 Sep 29.PMID: 32994187
196. Berra CC, De Fazio F, Azzolini E, Albin M, Zangrandi F, Mirani M, Garbossa S, Guardado-Mendoza R, Condorelli G, Folli F. Reply to letter to the editor by Bonaventura et al. *Acta Diabetol*. 2020 Jan;57(1):111-112. doi: 10.1007/s00592-019-01380-z. Epub 2019 Jun 24.PMID: 31236673
197. Berra C, Manfrini R, Regazzoli D, Radaelli MG, Disoteo O, Sommese C, Fiorina P, Ambrosio G, Folli F. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. *Pharmacol Res*. 2020 Oct;160:105052. doi: 10.1016/j.phrs.2020.105052. Epub 2020 Jul 8.PMID: 32650058
198. Assi E, D'Addio F, Mandò C, Maestroni A, Loretelli C, Ben Nasr M, Uselli V, Abdelsalam A, Seelam AJ, Pastore I, Magagnotti C, Abdi R, El Essawy B, Folli F, Corradi D, Zuccotti G, Cetin I, Fiorina P. Placental proteome abnormalities in women with gestational diabetes and large-for-gestational-age newborns. *BMJ Open Diabetes Res Care*. 2020 Nov;8(2):e001586. doi: 10.1136/bmjdr-2020-001586. PMID: 33188009
199. Pontiroli AE, La Sala L, Chiumello D, Folli F. Is blood glucose or obesity responsible for the bad prognosis of COVID-19 in obesity - diabetes? *Diabetes Res Clin Pract*. 2020 Sep;167:108342. doi: 10.1016/j.diabres.2020.108342. Epub 2020 Jul 27. PMID: 32730788
200. Fiorentino TV, Monroy A, Kamath S, Sotero R, Cas MD, Daniele G, Chavez AO, Abdul-Ghani M, Hribal ML, Sesti G, Tripathy D, DeFronzo RA, Folli F. Pioglitazone corrects

- dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. *Metabolism*. 2021 Jan;114:154416. doi: 10.1016/j.metabol.2020.154416. Epub 2020 Oct 31. PMID: 33137378
201. MF de la Luz Alvarez-Canales, SS Salazar-López, D Farfán-Vázquez, YE Martínez-López, JN González-Mena, LM Jiménez-Ceja, K Vargas-Ortiz, ML Evia-Viscarra MD, ML Montes de Oca-Loyola MD, F. Folli, A. Aguilar-García MD, R. Guardado-Mendoza. 2021 Effect of Linagliptin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients with Persistent Prediabetes After Metformin and Lifestyle *Sci Rep*. 2021 Apr 22;11(1):8750. doi: 10.1038/s41598-021-88108-8. PMID: 33888772
202. S De Martin, D Gabbia, F. Folli, F Bifari, P Fiorina, N Ferri, S Stahl, CE. Inturrisi, M Pappagallo, S Traversa, PL Manfredi. 2021. REL-1017 (esmethadone) increases circulating BDNF levels in healthy subjects undergoing a Phase 1 clinical study *Front Pharmacol*. 2021 Apr 28;12:671859. doi: 10.3389/fphar.2021.671859. eCollection 2021. PMID: 33995104
203. L Montefusco, M Ben Nasr, F D'Addio, C Loretelli, A Rossi, Pastore, G Daniele, A Abdelsalam, A Maestroni, M Dell'Acqua, E Ippolito, E Assi, V Usuelli, AJ Seelam, RM Fiorina, E Chebat, P Morpurgo, ME Lunati, AM Bolla, G. Finzi, R Abdi, JV. Bonventre, S. Rusconi, A. Riva, D. Corradi, PA Santus, M. Nebuloni, F. Folli, GV Zuccotti, M. Galli, P Fiorina. 2021
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection *Nat Metab*. 2021 Jun;3(6):774-785. doi: 10.1038/s42255-021-00407-6. Epub 2021 May 25. PMID: 34035524
204. Mancini M, Pecori Giralardi F, Andreassi A, Mantellassi G, Salvioni M, Berra CC, Manfrini R, Banderali G, Folli F. Obesity Is Strongly Associated With Low Testosterone and Reduced Penis Growth During Development. *J Clin Endocrinol Metab*. 2021 Oct 21;106(11):3151-3159. doi: 10.1210/clinem/dgab535. PMID: 34283215
205. Codella R, Della Guardia L, Terruzzi I, Solini A, Folli F, Varoni EM, Carrassi A, Luzi L. Physical activity as a proxy to ameliorate inflammation in patients with type 2 diabetes and periodontal disease at high cardiovascular risk. *Nutr Metab Cardiovasc Dis*. 2021 Jul 22;31(8):2199-2209. doi: 10.1016/j.numecd.2021.04.022. Epub 2021 May 5. PMID: 34099361
206. Bignotto M, Dei Cas M, Paroni R, Bianco E, Zermiani P, Gangale MG, Zadro V, Maregatti M, Piagnani A, Russo A, Baldassarre D, Folli F, Battezzati PM, Zuin CA.ME.LIA. An epidemiological study on the prevalence of Cardiovascular, METabolic, Liver and Autoimmune diseases in Northern Italy. *Nutr Metab Cardiovasc Dis*. 2021 May 6;31(5):1416-1426. doi: 10.1016/j.numecd.2021.02.001. Epub 2021 Feb 11. PMID: 33814235
207. Ceriani V, Pinna F, Galantino A, Zakaria AS, Manfrini R, Pontiroli AE, Folli F. Biliopancreatic Diversion (BPD), Long Common Limb Revisional Biliopancreatic Diversion (BPD + LCL-R), Roux-en-Y Gastric Bypass [RYGB] and Sleeve Gastrectomy (SG) mediate differential quantitative changes in body weight and qualitative modifications in body composition: a 5-year study. *Acta Diabetol*. 2021 Aug 28. doi: 10.1007/s00592-021-01777-9. Online ahead of print. PMID: 34453598
208. La Sala L, Tagliabue E, Vieira E, Pontiroli AE, Folli F. High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery. *Cardiovasc Diabetol*. 2021 Jun 9;20(1):118. doi: 10.1186/s12933-021-01310-w. PMID: 34107965
209. Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi CE, Manfredi PL-REL-1017 (Esmethadone) as Adjunctive Treatment in Patients with Major Depressive Disorder: a Phase 2a Double-Blind Randomized Trial- *Am J Psychiatry*. 2022 Feb;179(2):122-131. doi: 10.1176/appi.ajp.2021.21020197. Epub 2021 Dec 22. PMID: 34933568
210. D'Addio F, Maestroni A, Assi E, Ben Nasr M, Amabile G, Usuelli V, Loretelli C, Bertuzzi F, Antonioli B, Cardarelli F, El Essawy B, Solini A, Gerling IC, Bianchi C, Becchi G, Mazzucchelli S, Corradi D, Fadini GP, Foschi D, Markmann JF, Orsi E, Škrha J.Jr, Camboni MG, Abdi R, Shapiro AMJ, Folli F, Ludvigsson J, Del Prato S, Zuccotti GV, Fiorina P. The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. *Nat Commun*. 2022 Feb 3;13(1):684. doi: 10.1038/s41467-022-28360-2. PMID: 35115561.

211. Formenti P, Coppola S, Umbrello M, Froio S, Caccioppola A, De Giorgis V, Galanti V, Lusardi AC, Ferrari E, Noè D, Carnier S, Folli F, Chiumello D. Time course of the Bioelectrical Impedance Vector Analysis and muscular ultrasound in critically ill patients. *J Crit Care*. 2022 Apr;68:89-95. doi: 10.1016/j.jcrc.2021.11.014. Epub 2021 Dec 21. PMID: 34952476
212. Perego C, Di Cairano ES, Galli A, Moretti S, Bazzigaluppi E, Centonze VF, Gastaldelli A, Assi E, Fiorina P, Federici M, Porzio O, Bertuzzi F, Davalli AM, Folli F. Autoantibodies against the glial glutamate transporter GLT1/EAAT2 in Type 1 diabetes mellitus. Clues to novel immunological and non-immunological therapies. *Pharmacol Res*. 2022 Mar;177:106130. doi: 10.1016/j.phrs.2022.106130. Epub 2022 Feb 10. PMID: 35151858
213. Bifari F, Pappagallo M, Bleavins M, Folli F, Manfredi PL. REL-1017 (esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats. *Frontiers in Pharmacology- Neuropharmacology Section* 2022. Apr 25;13:863959. doi: 10.3389/fphar.2022.863959. eCollection 2022. PMID: 35571103
214. Ben Nasr M, D'Addio F, Laura Montefusco L, Uselli V, Loretelli C, Rossi A, Pastore I, Abdelsalam A, Maestroni A, Dell'Acqua M, Ippolito E, Assi E, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Abdi R Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Clark P, Nebuloni M, Baldi G, Finzi G, Folli F, Zuccotti GV, Galli M, Herold KC, Fiorina P. Indirect and direct effects of SARS-CoV-2 on human pancreatic islets. *Diabetes* 2022, Jul 1;71(7):1579-1590. doi: 10.2337/db21-0926 PMID: 35499468
215. Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, Ashworth J, Lanier R, Pappagallo M, Inturrisi C, Folli F, Traversa S, Manfredi PL. REL-1017 (Esmethadone; d-Methadone): Lack of Reinforcing Effect, Physical Dependence and Withdrawal in Sprague Dawley Rats *Sci Rep*. 2022 Jul 6;12(1):11389. doi: 10.1038/s41598-022-15055-3 PMID: 35794162
216. Bettini E, De Martin S, Inturrisi CE, Mattarei A, Pappagallo M, Stahl SM, Bifari F, Folli F, Traversa S, Manfredi PL. The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid and Gentamicin 2022. *Pharmaceuticals (Basel)*. 2022 Jul 17;15(7):882. doi:10.3390/ph15070882. PMID: 35890179
217. D'Addio F, Sabiu GM, Uselli V, Assi E, Abdelsalam A, Maestroni A, Seelam AJ, Ben Nasr M, Loretelli C, Mileto D, Rossi G, Pastore I, Montefusco L, Morpurgo P, Plebani L, Rossi A, Chebat E, Bolla AM, Lunati E, Mameli C, Macedoni M, Antinori S, Rusconi S, Gallieni M, Folli F, Berra C, Galli M, Gismondo MR, Zuccotti GV, Fiorina P. Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with Type 1 Diabetes. *Diabetes*. 2022 Aug 1;71(8):1800-1806. doi: 10.2337/db22-0053 PMID: 35551366
218. Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani S, Carignani C, Nola S, Locatelli P, Pappagallo M, Inturrisi CE, Bifari F, Cavalli A, Alimonti A, Pani L, Fava M, Traversa S, Folli F, Manfredi PL. Pharmacological comparative characterization of REL-1017 (esmethadone - HCl) and other NMDAR channel blockers in human heterodimeric N-methyl-D-aspartate receptors *Pharmaceuticals (Basel)*. 2022 Aug 13;15(8):997. doi: 10.3390/ph15080997 PMID: 36015145
219. Lazzaroni E, Lunati ML, Montefusco L, Pastore IF, Chebat E, Cimino V, Morpurgo P, Muratori M, Plebani L, Bolla AM, Rossi A, Vallone L, Gandolfi A, Tinari C, D'Addio F, Ben Nasr M, Loretelli C, Scaranna C, Bellante R, Manfrini R, Muratori F, Franzetti I, Orsi E, Gazzaruso C, Ghelardi R, Desenzani P, Genovese S, Girelli A, Folli F, Berra C, Fiorina P. 2022. Dapagliflozin acutely improves kidney function in type 2 diabetes: The PRECARE study (Pharmacological Research) 2022 Sep;183:106374. doi: 10.1016/j.phrs.2022.106374. Epub 2022 Jul 28. PMID: 35908663
220. Guidetti C, Serra G, Pani, L, Pappagallo M, Maglio G, Trasolini M, De Martin S, Mattarei A, Bifari F, Folli F, Manfredi PL, Fava M. REL-1017 (Esmethadone) May Rapidly Reduce

Dissociative Symptoms in Adults with Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of Two Cases.2022 (Journal of Clinical Psychopharmacology) 2022 Sep-Oct 01;42(5):503-506. doi: 10.1097/JCP.0000000000001583. Epub 2022 Aug 6. PMID: 35943402

221. Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. *Pharmacol Res.* 2022 Sep;183:106396. doi: 10.1016/j.phrs.2022.106396. Epub 2022 Aug 12. PMID: 35970329
222. Stahl SM, De Martin S, Mattarei A, Bettini E, Pani L, Guidetti C, Folli F, de Somer M, Traversa S, Inturrisi CE, Pappagallo M, Gentilucci M, Alimonti A, Fava M, Manfredi PL. Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling. *Int J Mol Sci.* 2022 Oct 13;23(20):12196. doi: 10.3390/ijms232012196. PMID: 36293063
223. Tobar N, Rocha GZ, Santos A, Guadagnini D, Assalin HB, Camargo JA, Gonçalves AESS, Pallis FR, Oliveira AG, Rocco SA, Neto RM, de Sousa IL, Alborghetti MR, Sforça ML, Rodrigues PB, Ludwig RG, Vanzela EC, Brunetto SQ, Boer PA, Gontijo JAR, Geloneze B, Carvalho CRO, Prada PO, Folli F, Curi R, Mori MA, Vinolo MAR, Ramos CD, Franchini KG, Tormena CF, Saad MJA. Metformin acts in the gut and induces gut-liver crosstalk. *Proc Natl Acad Sci U S A.* 2023 Jan 24;120(4):e2211933120. doi: 10.1073/pnas.2211933120. Epub 2023 Jan 19. PMID: 36656866
224. Guidetti C, Serra G, Pani L, Pappagallo M, Maglio G, Martin S, Mattarei A, Folli F, Manfredi PL, Fava M. Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder. *Prim Care Companion CNS Disord.* 2023 Feb 14;25(1):22m03267. doi: 10.4088/PCC.22m03267. PMID: 36821775
225. Pontiroli AE, Centofanti L, Le Roux CW, Magnani S, Tagliabue E, Folli F. Effect of Prolonged and Substantial Weight Loss on Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis. *Nutrients.* 2023 Feb 14;15(4):940. doi: 10.3390/nu15040940. PMID: 36839298
226. Piccini S, Favacchio G, Panico C, Morengi E, Folli F, Mazziotti G, Lania AG, Mirani M. Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. *Cardiovasc Diabetol.* 2023 Mar 25;22(1):69. doi: 10.1186/s12933-023-01800-z. PMID: 36966321
227. Shram MJ, Henningfield JE, Apseloff G, Gorodetzky CW, De Martin S, Vocci FL, Sapienza FL, Kosten TR, Huston J, Buchhalter A, Ashworth J, Lanier R, Folli F, Mattarei A, Guidetti C, Comai S, O'Gorman C, Traversa S, Inturrisi CE, Manfredi PL, Pappagallo M. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. *Transl Psychiatry.* 2023 Jun 7;13(1):192. doi: 10.1038/s41398-023-02473-8. PMID: 37286536
228. Berra C, Manfrini R, Mirani M, Bucciarelli L, Zakaria AS, Piccini S, Ghelardi R, Lunati ME, Rodovalho S, Bifari F, Fiorina P, Folli F. AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus. *Acta Diabetol.* 2023 Sep;60(9):1257-1266. doi: 10.1007/s00592-023-02115-x. Epub 2023 Jun 4. PMID: 37270748
229. Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, Alimonti A, Bifari F, Pani L, Folli F, Guidetti C, Furlan A, Sgrignani J, Locatelli P, Cavalli A, O'Gorman C, Traversa S, Inturrisi CE, Pappagallo M, Manfredi PL. Esmethadone-HCl (REL-1017): a promising rapid antidepressant. *Eur Arch Psychiatry Clin Neurosci.* 2023 Oct;273(7):1463-1476. doi: 10.1007/s00406-023-01571-4. Epub 2023 Mar 8. PMID: 36890259
230. Folli F, Finzi G, Manfrini R, Galli A, Casiraghi F, Centofanti L, Berra C, Fiorina P, Davalli A, La Rosa S, Perego C, Higgins PB. Mechanisms of action of incretin receptor based dual-

and tri-agonists in pancreatic islets. *Am J Physiol Endocrinol Metab.* 2023 Nov 1;325(5):E595-E609. doi: 10.1152/ajpendo.00236.2023. Epub 2023 Sep 20. PMID: 37729025

231. Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A, Franzetti IG, Muratori F, Manfrini R, Disoteco OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D'Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, Fiorina P. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. *Pharmacol Res.* 2024 Jan;199:107040. doi: 10.1016/j.phrs.2023.107040. Epub 2023 Dec 20. PMID: 38128857
232. Ferri N, De Martin S, Stuart J, Traversa S, Folli F, Pappagallo M, O'Gorman C, Guidetti C, Mattarei A, Inturrisi CE, Manfredi PL. Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism. *Drugs R D.* 2024 Mar;24(1):51-68. doi: 10.1007/s40268-023-00450-6. Epub 2023 Nov 27. PMID: 38010591
233. Folli F, Pontiroli AE, Zakaria AS, Centofanti L, Tagliabue E, La Sala L. Alanine transferase levels (ALT) and triglyceride-glucose index are risk factors for type 2 diabetes mellitus in obese patients. *Acta Diabetol.* 2024 Apr;61(4):435-440. doi: 10.1007/s00592-023-02209-6. Epub 2023 Dec 6. PMID: 38057389
234. Guidetti C, De Martin S, Serra G, Apicella M, Pani L, Pappagallo M, Mattarei A, Folli F, Manfredi P, Fava M. Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017). *J Clin Psychiatry.* 2024 May 13;85(2):22m14735. doi: 10.4088/JCP.22m14735. PMID: 38767937
235. Ferri N, De Martin S, Stuart J, Traversa S, Mattarei A, Comai S, Folli F, Pappagallo M, Guidetti C, Inturrisi CE, Manfredi PL. Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment. *Drugs R D.* 2024 Jun;24(2):341-352. doi: 10.1007/s40268-024-00477-3. Epub 2024 Aug 3. PMID: 39095578
236. Ben Nasr M, Usuelli V, Dellepiane S, Seelam AJ, Fiorentino TV, D'Addio F, Fiorina E, Xu C, Xie Y, Balasubramanian HB, Castillo-Leon E, Loreggian L, Maestroni A, Assi E, Loretelli C, Abdelsalam A, El Essawy B, Uccella S, Pastore I, Lunati ME, Sabiu G, Petrazzuolo A, Ducci G, Sacco E, Centofanti L, Venturini M, Mazzucchelli S, Mattinzoli D, Ikehata M, Castellano G, Visner G, Kaifeng L, Lee KM, Wang Z, Corradi D, La Rosa S, Danese S, Yang J, Markmann JF, Zuccotti GV, Abdi R, Folli F, Fiorina P. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. *Cell Metab.* 2024 Jun 4;36(6):1302-1319.e12. doi: 10.1016/j.cmet.2024.05.001. PMID: 38838642
237. Fava M, Stahl SM, Pani L, De Martin S, Cutler AJ, Maletic V, Gorodetzky CW, Vocci FJ, Sapienza FL, Kosten TR, Kröger C, Champasa P, O'Gorman C, Guidetti C, Alimonti A, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi CE, Manfredi PL, Pappagallo M. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial. *J Clin Psychiatry.* 2024 Jun 17;85(3):24m15265. doi: 10.4088/JCP.24m15265. PMID: 38917366
238. Galli A, Moretti S, Dule N, Di Cairano ES, Castagna M, Marciani P, Battaglia C, Bertuzzi F, Fiorina P, Pastore I, La Rosa S, Davalli A, Folli F, Perego C. Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis and treatment. *Am J Physiol Endocrinol Metab.* 2024 Jul 1;327(1):E27-E41. doi: 10.1152/ajpendo.00069.2024. Epub 2024 May 1. PMID: 38690938
239. Bignotto M, Bianco E, Centofanti L, Russo A, Dei Cas M, Zermiani P, Morano C, Samartin F, Bertolini E, Bifari F, Berra C, Zuin M, Paroni R, Battezzati PM, Folli F. Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population. CA.ME.LI.A study 7 year follow-up. *Am J Physiol Endocrinol Metab.*

MANUSCRIPT IN PRESS/ SUBMITTED FOR PUBLICATION/IN PREPARATION

1. Perego C, Di Cairano ES, Fino E, Bazzicaluppi E, Gastaldelli A, Centonze VE, Bertuzzi F, Davalli AM, Folli F. Autoantibodies to the Glial Glutamate Transporter Type 1 (GLT-1) in Type 1 Diabetes Mellitus. (*Manuscript in preparation*).
2. Folli F, Corbo M, Comi G, Moresco R, Fazio F, Galardi G, Fazio R., Perani D. Clinical and neuroimaging evidence of central nervous system involvement of the Gabaergic system in type 1 diabetes mellitus. (*Manuscript in preparation*).
3. Kamath S, Chavez AO, Davalli AM, Hubbard GB, Dick EJ, Palomo M, Halff GA, Abrahamian GA, Bastarrachea R, Comuzzie AG, Tripathy D, Gastaldelli A, DeFronzo RA, and Folli F. Insulin signaling defects in the liver of a non-human primate model of NAFLD. (*Manuscript in preparation*).
4. Chavez AO, Casiraghi F, Davalli AM, Kamath S, Ricotti A, Chang Z, Gastaldelli A, Abrahamian G.A, Halff GA, DeFronzo RA, Folli F. Insulin sensitivity, beta cell function and subclinical inflammation in the baboon, a non-human primate model of insulin resistance, obesity and type 2 diabetes. (*Manuscript in preparation*).
5. Perego C, Di Cairano ES, Fino E, Bazzicaluppi E, Gastaldelli A, Centonze VE, Bertuzzi F, Davalli AM, Folli F. The Glutamate transporter GLT1/EAAT2: a promising target to arrest beta cell dysfunction and death in diabetes mellitus. (*Manuscript in preparation*).
6. Folli F, Usuelli V, Fiorentino TV, Tezza S, Uccella S, Ben Nasr M, Bassi R, D'Addio F, Secchi A, La Rosa S, Fiorina P. The GLP1-R agonist exenatide exerts potent immunomodulatory effects and prolongs heart and islet of Langerhans allograft survival.
7. Mittestainer F., Folli F. Saad MJA. Molecular effects of atypical antipsychotic agents Olanzapine e Clozapine on insulin sensitivity and insulin secretion. (*Manuscript in preparation*)

ABSTRACTS:

1. Caro J, Cecchin F, Folli F, Sinha M. Triiodothyronine-induced insulin resistance in primary cultures of rat hepatocytes. *Annals Endocrinol.* 44:A87-A87, 1983.
2. Folli F, Solimena M, Comi GC, Bosi E, Pozza G, De Camilli P, Vicari AM. Stiff-man syndrome – type-1 (insulin dependent) diabetes mellitus – a common primary autoimmune pathogenesis. *Diabetologia* 30:A520-A520, 1987.
3. Solimena M, Piccolo G, Martino G, Folli F, Fratino P, De Camilli P. Autoantibodies directed against gabaergic nerve-terminals in a patient with idiopathic late-onset cerebellar-ataxia and type-1B diabetes mellitus. *Clin. Neuropath.* 7:211-211, 1988.
4. Folli F, Solimena M, Aparisi R, Pozza G, De Camilli P. Stiffman syndrome and type-1 (insulin-dependent) diabetes-mellitus – additional evidence suggesting a related autoimmune pathogenesis. *Diabetologia* 32:A488-A488, 1989.
5. Folli F, Saad MJA, Backer JM., Kahn CR. Insulin stimulates the PI-3 kinase associated with IRS-1 in liver and muscle of the intact rat. *Clin Res.* 40(2):A320-A320, 1992.
6. Goldfine AB., Folli F, Patti ME, Simonson DC, Kahn CR. Effects of sodium vanadate on in-vivo and in-vitro insulin action in diabetes. *Clin. Res.* 42:A116-A116, 1994.
7. Alvaro D, Folli F, Jezequel AM, Gigliozzi A, Kahn CR, Benedetti A. Involvement of phosphatidylinositol-3-kinase (PI3-K) IH regulation of endocytotic-transcytotic. *Hepatology* 22:809-809, (Suppl S), 1995.
8. Pigazzi A, Heydrick S, Folli F, Loscalzo J. Thrombin stimulates phosphoinositide 3-kinase-associated protein kinase activity in human platelets. *J Invest. Med.* 44:A214-A214, 1996.
9. Velloso LA, Folli F, Sun XJ, White MF, Saad MJA, Kahn CR. Cross-talk between insulin and angiotensin signaling. *J Invest. Med.* 44:A271-A271, 1996.
10. Pigazzi A, Folli F, Heydrich S, Loscalzo J. Nitric oxide inhibits thrombin induced phosphoinositide 3-kinase activity in human platelets. *Circulation* 94(8):1573-1573; (Suppl S), 1996.

11. Engleka MJ, Folli F, Winnay J, Kahn CR, McMorris F.A. Insulin-receptor substrate-1 is required for normal myelination. *J Neurochem.* 66(3):S20-S20; (Suppl 1), 1996.
12. Feener E, Hansen H, Folli F. Angiotensin II (AIT) inhibits insulin signaling in rat aortic smooth muscle cells (RASMC). *Diabetes.* 46:212-212 (Suppl 1), 1997
13. Baroni GS, Ridolfi F, Casini A, Bendia E, Gaggiotti G, Orlandoni P, Pontiroli AE, Benedetti A, Folli F. Differential effects of insulin and IGF-1 on human hepatic stellate cells mitogenesis and collagen synthesis: Role of PI 3and MAP-kinase pathways. *Hepatology.* 26(4):970-970;1997.
14. Sutti F, Perego L, Baglioni S, Otte A, Socci C, Aldrighetti L, Bertuzzi F, Pozza G, Pontiroli AE, Davalli AM, Folli F. In search of diabetogenes by differential display of messenger RNA from human islets of langerhans. *Diabetologia* 42:A149-A149; (Suppl; 1), 199
15. Meoni C, Bertuzzi F, Pontiroli AE, Falqui L, Arcelloni C, Paroni R, Sala L, Folli F, Davalli AM. Regulated proinsulin gene expression and mature insulin secretion by GH3 cells stably transfected with a furin-cleavable human proinsulin cDNA. *Diabetologia* 42:A148-A148 (Suppl 1), 1999.
16. Federici M, Hribal M, Perego L, Bonini P, Bertuzzi F, Marchetti P, Davalli A, Mangili F, Lauro R, Sesti G, Folli F. High glucose modulates expression of bcl-2 family genes towards an apoptotic program in cultured human pancreatic islets. *Diabetes* 49:A273-A273; (Suppl 1), 2000.
17. Pizzocri PL, Pontiroli AE, Librenti MC, Vedani P, Marchi M, Folli F, Cucchi E, Orena C, Ferla GF, Paganelli M, Giacomelli M. Laparoscopic adjustable gastric banding (LAGB) for management of obesity-linked type 2 diabetes and arterial hypertension: Comparison with traditional treatment. *Diabetologia* 43:A4-A4; (Suppl 1), 2000.
18. Ciccarone AM, Bertacca A, Chiellini C, Novelli S, Canello R, Zingaretti C, Soukas A, Folli F, Perego L, Pontiroli A, Dimitri R, Gandini D, Bottone P, Ferrari M, Massei A, Benzi L, Cinti S, Navalesi R, Maffei M. Analysis of haptoglobin expression in rodent and human obesity. *Diabetologia* 43:A174-A174; (Suppl 1), 2000.
19. Ridolfi F, Svegliati G, Perego L, Marucci L, Di Sario A, Benedetti A, Folli F. Differential ERK1/2 activation in rat chronic liver injury and fibrosis. *J Hepatol.* 34:78-78; (Suppl 1), 2001.
20. Folli F, Pizzocri P, Busia A, Bianco S, Gambaro G, Robuschi M, Pontiroli A. Exhaled nitric oxide is reduced in morbid obesity. *Diabetes* 50:A532-A532; (Suppl 2), 2001.
21. Folli F, Fiorina P, Finzi G, Properzi G, Usellini L, Caradonna Z, Pedale R, Socci C, Orsenigo E, La Rocca E, Bertuzzi F, Di Carlo V, Pozza G, Capella C, Secchi A. Skin microangiopathy in type 1 diabetic-uremic patients after kidney-pancreas, kidney-islet or kidney transplantation. *Diabetes* 50:A410-A411; (Suppl 1), 2001.
22. Fiorina P, Maffi P, Folli F, Properzi G, Venturini M, Minicucci F., Monti L, Valsecchi G, Sblendido M, Passoni A, Bertuzzi F, Socci C, Di Carlo V, Del Maschio A, Pozza G., Secchi A. Long term islet function improves endothelial function, nitric oxide production and preserved vascular function in uremic type 1 diabetic kidney transplanted patients. A possible role for C-peptide secretion. *Diabetes* 50:A153-A154, (Suppl 2), 2001.
23. Fiorina P, Bifari F, Pellagatta F, Melandri M, Fedeli C, Veschini L, Ferrero E, Pozza G, Di Carlo V, Folli F, Secchi A. Normalization of platelets chronic activation after kidney-pancreas transplantation in uremic type 1 diabetic patients. A possible role for PAR1-PAR3 receptor. *Diabetologia* 44:A73-A73, 200
24. Alvaro D, Alpini G, Onori P, Glaser S, Baroni-Svegliati G, Folli F, Franchitto A, Attili A, Gaudio E. Estrogens stimulate cholangiocyte proliferation through the activation of the ERK1/2 system and the adapter protein Sch. *Hepatology* 34:477A-477A; (Suppl S), 2001.
25. Svegliati-Baroni G, Ridolfi F, Taffetani S, Saccomanno S, Trozzi L, Caradonna Z, Folli F, Benedetti A. Cellular signaling during liver injury leading to hepatic fibrosis in vivo. *J Hepatol.* 36:75-75; (Suppl 1), 2002.
26. Pontiroli AE, Pizzocri P, Librenti MC, Vedani P, Marchi M, Cucchi E, Orena C, Paganelli M, Ferla G, Folli F. Laparoscopic adjustable gastric banding for the treatment of morbid obesity and its metabolic complications. A three-year study. *Diabetes* 51:A414-A414; (Suppl 2), 2002.
27. Perego L, Hribal M, Lovari S, Menghini R, Finzi G, Lauro D, Bertuzzi F, Davalli A, Pontiroli A, Federici M, Brunetti A, Sesti G, Folli F. Insulin receptor signaling apparatus is found in insulin secretory granules. Chronic hyperglycemia impairs insulin receptor expression and function in pancreatic beta-cell. *Diabetes* 51:A397-A397; (Suppl 2), 2002.
28. Fiorina P, Folli F, Maffi P, Bertuzzi F, Venturini M, Pedale R, Di Carlo V, Del Maschio A,

- Capella C, Secchi A. Long term beneficial effect of islet transplantation on diabetic complications in type 1 diabetic kidney transplanted patients. A study of 34 consecutive cases. *Diabetes* 51:A34-A34; (Suppl 2), 2002.
29. Pontiroli AE, Pizzocri P, Librenti MC, Vedani P, Marchi M, Cucchi E, Orena C, Paganelli M, Giacomelli M, Ferla G, Folli F. Laparoscopic adjustable gastric banding for the treatment of morbid obesity and its metabolic complications. A three-year study. *Diabetologia* 45:A269-A270; (Suppl 2), 2002.
30. Ridolfi F, Saccomanno S, Candelaresi C, Sterpetti P, Benedetti A, Folli F, Baroni G.S. Regulation and crosstalk of ERK/JNK/p70S6K in hepatic stellate cells: An in vivo and in vitro study. *J Hepatol.* 38:81-81; (Suppl 2), 2003.
31. Fiorina P, Folli F, Maffi P, Bertuzzi F, Finzi G, Davalli A, La Rosa S, Capella C, Secchi A. Long-term beneficial effect of islet transplantation on diabetic macro/microangiopathy in type I diabetic kidney transplanted patients. *Cell Transplant.* 12:153-154, 2003.
32. D'Alessandris C, Perego L, Federici M, Bertuzzi F, Lauro R, Folli F, Sesti G. Expression profiling of pancreatic beta-cell exposed to high glucose and glucosamine. *Diabetes.* 52:A353-A353(Suppl 1), 2003.
33. Pontiroli AE, Pizzocri P, Koprivec D, Vedani P, Marchi M, Arcelloni C, Paroni R, Esposito K, Folli F, Giugliano D. Greater effect of body weight than of glucose metabolism on ICAM-1 E-selectin, and endothelin-1 levels in humans. *Diabetes.* 52:A394-A394 (Suppl 1), 2003.
34. Folli F, Fiorina P, Fedeli C, Finzi G, Placidi C, Della Valle P, Ferrero E, Capella C, Secchi A. Amelioration of haemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. *Diabetes.* 52:A468-A468 (Suppl 1), 2003.
35. Fiorina P, Folli F, Fedeli C, Finzi G, Placidi C, Della Valle P, Ferrero E, Capella C, Secchi A. Amelioration of haemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. *Transplantation.* 76(4):544-544, 2003.
36. Folli F, Moresco R, Ortelli P, Gobbo C, Campori E, Panzacchi A, Fiorina P, Secchi A, Matarrese M, Corbo M, Rodegher M, Fazio R, Fazio F, Perani D. RCBF/SPECT, 11C-flumazenil/PET and behavioural findings in patients affected by type I diabetes mellitus. *Diabetes.* 52:A570-A570 (Suppl 1), 2003.
37. Fiorina P, Folli F, Maffi P, Zerbini G, Bertuzzi F, Gremizzi C, Davalli A, Di Carlo V, Kashgarian M, Secchi A. Improvement of renal function after islet successful transplantation in uremic type I diabetic kidney transplanted patients. *Cell. Transplant.* 12(2):154-154, 2003.
38. Fiorina P, Folli F, Maffi P, Bertuzzi F, Finzi G, Davalli A, LaRosa S, Capella C, Secchi A. Long-term beneficial effect of islet transplantation on diabetic macro/microangiopathy in type I diabetic kidney transplanted patients. *Cell Transplant.* 12(2):153-154, 2003.
39. Folli F, Pizzocri P, Vardaro D, Perego L, Pontiroli AE. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension in morbid (Grade 3) obesity: A 4 year study. *Diabetes* 53:A594-A594; (Suppl 2), 2004.
40. Guzzi V, Perego L, Fiorina P, Gregorini L, Bachi A, Secchi A, Folli F. Proteomic analysis of skin biopsies from type 1 diabetic uremic patients. Effect of kidney-pancreas transplantation. *Diabetes* 53:A453-A453; (Suppl 2), 2004.
41. Pizzocri P, Laneri M, Veronelli A, Guzzi VR, Folli F, Rognoni C, Vedani P, Vardaro D, Pontiroli A.E. White blood cells in obesity-diabetes: Effects of weight loss and of normalization of glucose metabolism. *Diabetes* 53:A415-A415; (Suppl 2), 2004.
42. Adamo MD, Perego L, Cardellini M, Laratta E, Marini MA, Andreozzi F, Sciacqua A, Pontiroli AE, Lauro R, Perticone F, Folli F, Sesti G. The-866A/A genotype of the uncoupling protein 2 (UCP2) gene is associated with insulin resistance and increased risk of type diabetes mellitus. *Diabetes* 53:A270-A270; (Suppl 2), 2004.
43. Pontiroli AE, Pizzocri P, Paganelli M, Folli F. Laparoscopic gastric banding prevents Type 2 diabetes and arterial hypertension in morbid (grade 3) obesity: a 4 year study. *Diabetologia* 47:A150-A150 (Suppl 1), 2004.
44. Fiorina P, Folli F, Ferrero E, Orsenigo E, Finzi G, Mazzolari G, Placidi C, Perego L, La Rosa S, Melandri M, Monti L, Capella C, D'Angelo A, Staudacher C, Secchi A. Morphological and functional differences in haemostatic axis between kidney transplanted and end stage renal disease patients. *A J of Transplant.* 5:197-197; (Suppl 11), 2005.
45. Sesti G, Perego L, Cardellini M, Andreozzi F, Ricasoli C, Vedani P, Guzzi V, Marchi M, Paganelli M, Ferla G, Pontiroli AE, Hribal ML, Folli F. Impact of common polymorphism candidate genes for insulin resistance and obesity on weight loss of morbidly obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet (vol. 90, pg. 5064, 2005). *J*

Clin Endocrinol Metab. 90(10):5810-5810;2005.

46. Folli F, Perego C, Okada T, Perego L, D'Amico A, Sesti G, Kulkarni RN. Islet beta- and alpha-cell replication: An important feature of human type 2 diabetes. *Diabetes*. 54:A398-A398; (Suppl 1);2005.
47. Guzzi V, Perego L, Fiorina P, Bachi A, Paroni R, Secchi A, Folli F. Proteomics reveals increased oxidative stress as a major alteration in diabetic (T1DM) and diabetic uremic (U+T1DM) patients. Effect of kidney-pancreas (KP) transplantation. *Diabetes* 54:A487-A487; (Suppl 1), 2005.
48. Folli F, Perego L, Cardellini M, Andreozzi F, Ricasoli C, Guzzi V, Pontiroli AE, Hribal M.L., Sesti G. Impact of common polymorphisms in candidate genes on weight loss of morbidly obese subjects (Grade III, WHO) after laparoscopic adjustable gastric banding (LAGB). *Diabetes* 54:A436-A437; (Suppl 1), 2005.
49. Cardellini M, Perego L, Marini MA, Giacomelli M, Paganelli M, Pontiroli AE, Lauro R, Folli F, Sesti G. The G-174G genotype in the promoter of the interleukin-6 gene is associated with insulin resistance. *Diabetes* 54:A278-A278; (Suppl 1), 2005.
50. Hribal ML, Perego L, Cardellini M, Paganelli M, Andreozzi F, Pontiroli AE, Folli F, Sesti G. Gene expression profiling in adipose tissue of G972R IRS-1 carriers. *Diabetes* 54:A270-A271; (Suppl 1), 2005.
51. Guzzi V, Salvati E, Biroccio A, Perego L, Chiesa R, Castellano R, Florina P, Federici M, Urbani A, Folli F. Proteomic profiles of carotid atherosclerotic plaques from type 2 diabetic and non-diabetic patients. *Diabetes* 54:A180-A180; (Suppl 1), 2005.
52. Perani D, Panzacchi A, Garibotto V, Moresco RM, Ortelli P, Carpinelli A, Folli F, Fazio F. Decreased cerebral GABA-A receptors in Stiff Person Syndrome. *Neurology* 66:A134-A134; (Suppl 2), 2006.
53. Voruganti S, DeFronzo RA, Alvarenga J, Triplitt C, Chavez A, Folli F, Bastarrachea R, Comuzzie A. Changes in plasma ghrelin and peptide YY during hyperinsulinemic-euglycemic clamp in baboons. *Diabetes* 55:A347-A347;(Suppl 1), 2006.
54. Federici M, Menghini R, Perego L, Martelli E, Lauro D, Porzio O, Mauriello A, Pontiroli AE, Lauro R, Folli F. Reduced TIMP3 levels in atherosclerotic plaques from patients affected by altered glucose tolerance. *Diabetes* 55:A156-A156; (Suppl 1), 2006.
55. Folli F, Menghini R, Martelli E, Rizza S, Lauro R, Federici M. Reduced TIMP3 levels in atherosclerotic plaques from patients affected by type 2 diabetes and impaired glucose tolerance. *Diabetologia* 49:732-733; (Suppl 1), 2006.
56. Weintraub S, Carroll CA, Kamath S, Monroy A, Chavez-Velazquez AO, DeFronzo R, Folli F. Progress toward a biomarker discovery-to-verification pipeline in clinical proteomics. *Mol Cell Proteomics*. 6(8):67-67;(Suppl S).
57. Tantiwong P, Chavez A, Lopez-Alvarenga JC, Bastarrachea RA, Triplitt C, Sriwijitkamol A, Comuzzie AG, Folli F, DeFronzo RA, Musi N. Insulin signaling in muscle and fat from baboons. *Diabetes* 56:A664-A664; (Suppl 1), 2007.
58. Gastaldelli A, Perego L, Sesti G, Hribal M, Sironi AM, Paganelli M, DeFronzo RA, Pontiroli AE, Folli F. High prevalence of elevated liver enzymes and glucose intolerance in morbid obese patients are reduced after laparoscopic adjustable gastric banding (LAGB). *Diabetes* 56:A693-A693; (Suppl 1), 2007.
59. Pontiroli AE, Fossati A, Vedani P, Fiorilli M, Marchi M, Folli F, Paganelli M, Maffei C. Narcissistic personality, post-surgery compliance, and adherence to scheduled visits predict outcome of bariatric restrictive surgery in morbidly obese patients. *Diabetes* 56:A692-A692; (Suppl 1), 2007.
60. Frige F, Laneri M, Veronelli A, Folli F, Paganelli M, Vedani P, Marchi M, Noe D, Ventura P, Opocher E, Pontiroli AE. Malabsorptive surgery is more effective than restrictive bariatric surgery in morbid obesity: Improvements of glucose metabolism are proportional to decrease of fat mass, not of fat-free mass. *Diabetes* 56:A692-A692; (Suppl 1), 2007.
61. Tripathy D, Chavez-Velazquez AO, Jani R, Abdul-Ghani MA, Frohlich V, Padma S, Jenkinson CP, Folli F, DeFronzo RA. Short-term elevation of plasma free fatty acids (FFA) decreases skeletal muscle mitochondrial membrane potential in healthy glucose tolerant subjects. *Diabetologia* 50:S79-S80; (Suppl 1), 2007.
62. Chavez AO, Lopez-Alvarenga JC, Tejero ME, Triplitt C, Bastarrachea RA, Sriwijitkamol A, Tantiwong P, Voruganti VS, Musi N, Comuzzie AG, DeFronzo RA, Folli F. Fasting plasma glucose and haemoglobin A1c predict baboon pancreatic islet amyloidosis: a novel non-human primate model for type 2 diabetes mellitus (T2DM). *Diabetologia* 50:S186-S186; (Suppl 1),

2007.

63. Chavez AO, Lopez JC, Triplitt C, Tantiwong P, Sriwijitkamol A, Bastarrachea R, Voruganti VS, Leland M, Comuzzie A, Musi N, DeFronzo RA, Folli F. The baboon (*Papio hamadryas*) as a model of insulin resistance: In vivo characterization using the euglycemic insulin clamp. *Diabetes* 56:A452-A452; (Suppl 1), 2007.
64. Monroy A, Federici M, Menghini R, Chavez AO, Frolich V, Svrijitamol A, Barrentine A, Coletta D, Musi N, Tripathy D, DeFronzo RA, Folli F. Increased proinflammatory TNF α converting enzyme (TACE) in skeletal muscle plays a role in insulin resistance in human type 2 diabetes mellitus (T2DM). *Diabetes* 56: A396-A396; (Suppl 1), 2007
65. Federici M, Cardellini M, Menghini R, Rizza S, Savo A, Folli F, Lauro R. Tace/Adam17 is activated in vascular system of prediabetic and diabetic subjects. *Diabetes* 56: A175-A175; (Suppl 1), 2007.
66. Chavez AO, Jani R, Abdul-Ghani A, Frohlich V, Sathyanarayana P, Jenkinson CP, Folli F, DeFronzo RA, Tripathy D. Short-term elevation of plasma free fatty acids (FFA) decreases skeletal muscle mitochondrial membrane potential in healthy glucose tolerant subjects. *Diabetes* 56:A63-A63; (Suppl 1), 2007.
67. Rizza S, Menghini R, Martelli E, Clementi F, Ippoliti A, Romeo F, Folli F, Federici M. Role of ectodomain shedding activity from metabolic syndrome to carotid and coronary artery disease. *Diabetologia* 51:S533-S533; (Suppl 1), 2008.
68. Chavez AO, Kamath S, Guardado-Mendoza R, Hubbard G, Dick E, Comuzzie A, Gastaldelli A, DeFronzo RA, Folli F. Characterization of the insulin signaling cascade defects in the liver of obese-insulin resistant baboons. *Diabetologia* 51:S293-S293; (Suppl 1), 2008.
69. Folli F, Davalli A, Chavez AO, Comuzzie A, Tejero E, Zuo P, Chang Z, Dick Jr E, Hubbard G, Cruz A, Perez C, Halff G, Gastaldelli A, DeFronzo RA, Guardado-Mendoza R. Development of a predictive model for pancreatic islet amyloidosis in the baboon based on fasting plasma glucose and age. Implication for the study of beta cell failure in human type 2 diabetes. *Diabetologia* 51:S218-S218; (Suppl 1), 2008.
70. Pontiroli AE, Frige F, Paganelli M, Folli F. In morbid obesity metabolic abnormalities and adhesion molecules correlate with visceral fat; effect of weight loss through surgery. *Diabetes* 57:A482-A482; (Suppl 1), 2008.
71. Mendoza RG, Davalli AM, Chavez AO, Comuzzie A, Tejero E, Alvarenga JC, Bastarrachea R, Zuo P, Chang Z, Dick E, Hubbard G, Cruz AM, Perez CT, Halff G, DeFronzo RA, Folli F. Effect of obesity and leptotoxicity on pancreatic islet of Langerhans Amyloidosis in the baboon, a new model of type 2 diabetes mellitus (T2DM). *Diabetes* 57:A476-A476; (Suppl 1), 2008.
72. Mendoza RG, Davalli AM, Chavez AO, Comuzzie A, Tejero E, Alvarenga JC, Bastarrachea R, Zuo P, Chang Z, Dick E, Hubbard G, Cruz AM, Perez CT, Halff G, DeFronzo RA, Folli F. Fasting plasma glucose (FPG) and HbA1c predict quantitatively baboon pancreatic islet amyloidosis (PIA): a novel non-human primate model of β -cell failure in type 2 diabetes mellitus (T2DM). *Diabetes* 57:A439-A439; (Suppl 1), 2008.
73. Monroy A, Carroll C, Chavez AO, Barrentine A, Abdul-Ghani MA, Tripathy D, Weintraub S, DeFronzo RA, Folli F. Mitochondrial proteomics of human type 2 diabetic skeletal muscle reveals downregulation of selected respiratory chain components. *Diabetes* 57:A429-A429; (Suppl 1), 2008.
74. Chavez AO, Molina-Carrion M, Abdul-Ghani M, Folli F, DeFronzo RA, Tripathy D. Fibroblast growth factor-21 (FGF-21), a novel peptide, is associated with whole body and hepatic insulin resistance. *Diabetes* 57:A33-A34; (Suppl 1), 2008.
75. Chavez AO, Guardado-Mendoza R, Iannucci CV, Folli F, Kamath S, DeFronzo RA, Tripathy D. Plasma Insulin and Glucagon Responses to a Maximal Hyperglycemic Stimulus with Impaired Glucose Tolerance (IGT) and Type 2 Diabetes Mellitus (T2DM). *Diabetes* 58:A379-A380; (Suppl 1), 2009.
76. Cardellini M, Rizza S, Menghini R, Martelli E, Clementi F, Ippoliti A, Romeo F, Folli F, Federici M. Role of ectodomain shedding activity from metabolic syndrome to carotid and coronary artery disease. *Diabetes*: 58: A419-A419 (Suppl1), 2009.
77. Mendoza, RG, Davalli A, Chavez-Velazquez AO, Comuzzie A, Tejero, Alvarenga JC, Bastarrachea R, Zuo P, Chang Z, Dick E, Hubbard G, Cruz AM, Perez CT, Halff, G DeFronzo RA; Folli, F. Fasting plasma glucose (FPG) and HbA1c predict quantitatively baboon pancreatic islet amyloidosis (PIA): A novel non-human primate model of beta-cell failure in type 2 diabetes Mellitus (T2DM) *Diabetologia* 51: S218-S218 (Suppl 1), 2008
78. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard G, Dick Jr. E, Majluf-Cruz A,

- Tene-Perez CE, Jimenez-Ceja LM, Casiraghi F, Kamath S, Finzi G, Placidi C, Larosa S, Capella C, Halff G, Gastaldelli A, DeFronzo RA, Folli F. Pancreatic Islet Amyloidosis and Hyperglycemia Are Associated to Beta Cell Apoptosis, Alpha Cell Proliferation and Hyperglucagonemia in Non-Human Primates. *Diabetes* 58:A404; (Suppl 1), 2009.
79. Guardado-Mendoza R, Chavez-Velazquez AO, Folli F, Iannucci CV, DeFronzo RA, Tripathy D. Reduced Amylin (IAPP) Secretion in Response to Hyperglycemia and Arginine Are Characteristic of Impaired Glucose Tolerance and Type 2 Diabetes. *Diabetes* 58:A419; (Suppl 1), 2009.
 80. Chavez AO, Guardado-Mendoza R, Iannucci CV, Folli F, Kamath S, Jhingan RM, DeFronzo RA, Tripathy D. Plasma insulin and glucagon responses to a maximal hyperglycaemic stimulus and arginine infusion in subjects with impaired glucose tolerance and type 2 diabetes mellitus. *Diabetologia* 52:S105; (Suppl 1), 2009.
 81. Tripathy D, Guardado-Mendoza R, Chavez AO, Folli F, Iannucci CV, Jhingan RM, DeFronzo RA. Reduced amylin (IAPP) secretion in response to hyperglycaemia and arginine are characteristic of impaired glucose tolerance and type 2 diabetes. *Diabetologia* 52:S107; (Suppl 1). 2009.
 82. Folli F, Davalli AM, Chavez AO, Hubbard G, Dick Jr E, Finzi G, Placidi C, La Rosa S, Capella C, Jimenez-Ceja LM, Casiraghi F, Subhash K, Palomo M, Halff G, Gastaldelli A, DeFronzo RA, Guardado-Mendoza R. Effect of Glucose Abnormalities and Pancreatic Islet Amyloidosis on the Cell Composition of the Islets of Langerhans in Non-Human Primates. *Diabetologia*. 52:S165; (Suppl 1), 2009.
 83. Monroy A, Federici M, Chavez AO, Kamath S, Reyna S, Palomo M, Musi N, Tripathy D, DeFronzo R, Folli F. Impaired regulation of tace/timp3 proteolytic system in skeletal muscle of obese type 2 diabetic subjects. A new mechanism of insulin resistance in humans. *Atherosclerosis* (Suppl) Volume: 10 Issue 2, 2009.
 84. Cardellini, M, Menghini, R, Martelli E, Rizza S, Porzio O, Mauriello A, Spagnoli L, Romeo F, Solini A, Ippoliti A, Lauro R, Folli F, Federici M. Insulin resistance and atherosclerosis are characterized by increased activity of the ectodomain shedding process. *Atherosclerosis* (Suppl) Volume: 10 Issue: 2, 2009.
 85. Fowler AR, Blanco CL, Folli F. The ontogenesis of the endocrine pancreas in the premature baboon model. *Journal of Investigative Medicine* 58: 488-488, 2010.
 86. Vergani A, Guzzi V, Perego L, Coletta D, La Rosa S, Capella C, Jenkinson C, Secchi A, Bachi A, Brownlee M, Fiorina P, Folli F. Persistent Cellular Changes of the Heat Shock Protein System and of the Anti-Oxidative Machinery in Skin Vessels of Type 1 Diabetic Patients Are Reverted during Restoration of Normoglycemia after Pancreas Transplantation. *American Journal of Transplantation* 10 Special Issue: SI Suppl.: 4 Pages: 113-113, 2010.
 87. Kamath S, Chavez AO, Davalli A, Hubbard GB, Dick EJ, Palomo M, Halff G, Abrahamian G, Bastarrachea R, Comuzzie AG, Tripathy D, Gastaldelli A, DeFronzo RA, Folli F. Insulin Signaling Defects in the Liver of a Non-Human Primate Model of NAFLD. *Diabetes*: 59: A415-A415 (Suppl 1) 2010.
 88. Guardado-Mendoza R., Jimenez-Ceja LM, Davalli A, Navarro C, Abrahamian, G, Halff G, DeFronzo RA, Gastaldelli A, Folli F. Impact of Obesity Duration and Severity on Islet of Langerhans' Remodeling in Normoglycemic Baboons. *Diabetes*: 59: A475-A476 (Suppl. 1) 2010.
 89. Chavez AO, Guardado-Mendoza R, Folli F, DeFronzo RA, Tripathy D. Effect of Pioglitazone, Exenatide, and Combined Pioglitazone Plus Exenatide Therapy on Beta Cell Function in Type 2 Diabetes Mellitus. *Diabetes*; 59 A85-A85 (Suppl: 1) 2010
 90. Casiraghi F, Lertwattanak R, Chavez-Velazquez A, Palomo M, DeFronzo RA, Luzi, L, Musi N, Folli F. SenseWear Armband Is a Simple and Reliable Tool To Measure Energy Expenditure in Humans. Comparison with Indirect Calorimetry. *Diabetes*: 59, A627-A627 (Suppl1) 2010.
 91. Folli, F, Chavez AO, Casiraghi, F, Davalli A, Halff GA, Abrahamian G, Hubbard G, Dick E, Comuzzie A, Bastarrachea RA, Tripathy, D, Gastaldelli A, DeFronzo R, Kamath S. The baboon as a model of non-alcoholic fatty liver disease (NAFLD). increased intra-hepatic fat content and impairment in the insulin signaling cascade in obese/insulin resistant non-human primates. *Hepatology*: 52: 1059A-1059A (Suppl: S) 2010
 93. Subhash Kamath, Monroy A, Chavez AO, Wilson MA, Carroll CA, Casiraghi F, Tripathy D, Weintraub SE, DeFronzo RA, and Folli F. Proteomic and ingenuity pathway analysis of skeletal muscle mitochondria in type 2 diabetes patients suggests altered regulation of specific

- fatty acid oxidation and TCA cycle enzymes. *Endocrine Reviews* 32: A509, 2011.
94. Kamath S, Chavez AO, Casiraghi F, Cline G, Davalli A, Halff G, Abrahamian G, Bastarrachea R, Comuzzie A, Gastaldelli A., Federici M, Marzano V, Urbani A, De Fronzo RA, Folli F. Critical role of triglycerides and long chain fatty acyl Coa accumulation in liver insulin resistance in the baboon. a new non-human primate model of NAFLD. *Journal of Hepatology*: 54 : S499-S499 (Suppl. 1) 2011.
 95. Higgins PB, Bauer C, Folli F, Garcia-Forey M, Voruganti VS, Bastarrachea R, Nathanielsz PW, Shade RE, Comuzzie A. Methodology For Performing Intracerebroventricular Infusions During Metabolic Studies in Conscious Non-Human Primates. *Obesity*: 19: S93-S94 (Suppl.1) 2011.
 96. Casiraghi F, Chavez AO, Davalli, AM, Abrahamian GA, Gastaldelli, A, Bastarrachea RA, Kamath S, Petz R, Zuo P, Ricotti A, Higgins PB, Comuzzie A, Halff GA, DeFronzo RA, Folli F. Continuous exenatide infusion markedly improves insulin sensitivity and disposition index in partially pancreatectomised baboons. *Diabetologia*: 54 Pages: S213-S214; Suppl. 1; 2011
 97. Chavez AO, Guardado-Mendoza R, King JW, Kincade J, Folli F; DeFronzo, RA, Tripathy D. Differential effect of pioglitazone, exenatide and combination of pioglitazone and exenatide on adipocyte insulin resistance in type 2 diabetes. *Diabetologia* 54 Pages: S213-S213; (Suppl. 1) 2011.
 98. Folli F, Casiraghi F, Davalli AM, Kamath S, Ricotti A, Chang Z, Gastaldelli A, Abrahamian GA, Halff GA, DeFronzo RA, Chavez AO. Insulin sensitivity, beta cell function and subclinical inflammation in the baboon, a non human primate model of insulin resistance, obesity and type 2 diabetes. *Diabetologia* 54 Pages: S272-S273 (Suppl 1) 2011.
 99. Casiraghi F, Chavez AO, Davalli A, Abrahamian GA, Gastaldelli A, Bastarrachea R, Kamath S, Petz R, Zou P, Higgins P, Chang Z, Comuzzie A, Halff G, DeFronzo RA, Folli F. Effect of Continuous Exenatide Infusion on Insulin Action and Secretion in Partially Pancreatectomized Baboons. *Diabetes*, Suppl 1, 1638-P; 2011
 100. Andreozzi F, Procopio C, Greco A, Mannino GC, Miele C, Raciti GA, Iadicicco C, Beguinot F, Pontiroli AE, Hribal ML, Folli F, Sesti G. Increased Expression of the Akt-Specific Phosphatase PH Domain Leucine-Rich Repeat Protein Phosphatase 1 (PHLPP-1) in Obese Subjects Is Associated with Insulin-Resistance *Diabetes*, Suppl 1; 1864-P; 2011
 101. Daniele G, Perez-Cadena Z, Chavez-Velazquez A, Kamath S, Zuo P, Chang Z, Andreozzi F, Paez AM, Fanti P, Gastaldelli A, DeFronzo RA, Tripathy D, Folli F. Plasma Fractalkine is associated with adipose Tissue Insulin Resistance and Low-Dose Pioglitazone Reduces Fractalkine Parallel with Reduced Adipose Tissue Insulin Resistance in Type 2 Diabetes. *Diabetes* Suppl. 1, vol. 61; 1029P; 2012.
 102. Daniele G., Perez-Cadena Z, Chavez-Velazquez A, Kamath S, Zuo P, Chang Z, Andreozzi F, Paez AM, Fourcadot M, Winnier W, Arya R, Hannis-Diarte A, Jenkinson C, Fanti P, Gastaldelli A, DeFronzo RA, Tripathy D, Folli F. Low-Dose (15 mg/day) Pioglitazone Treatment Improves Glycemic and sub-inflammatory State in Obese Type 2 Diabetic- Subjects in 24 week Intervention Study. *Diabetes* Suppl. 1, vol. 61; 1064P; 2012.
 103. Perez-Cadena Z, Daniele G , Chavez-Velazquez A, Kamath S, Zuo P, Chang Z, Andreozzi F, Paez AM, Winnier W, Arya R, Hannis-Diarte A, Cortez L, Jenkinson C, Fanti P, Gastaldelli A, DeFronzo RA, Tripathy D, Folli F. Low-Dose (15mg/day) Pioglitazone Treatment Improves Glycemic Control, and Whole-Body and Adipocyte Insulin Resistance with Minimal Weight Gain in Type Diabetic Subjects. *Diabetes* Suppl. 1, vol. 61; 1090P; 2012.
 104. Andreozzi F, Gastaldelli A, Mannino G, Kamath S, Succurro E, Arturi F, Daniele G, Sciaqua A, Perticone F, Folli F, Sesti G. Hepatic Insulin resistance is a Predictor of Cardiometabolic Disease. *Diabetes* Suppl. 1, vol. 61; 1809P; 2012.
 105. Perego C, Di Cairano ES, Fino E, Bazzini, C, Bazzigaluppi E, Gastaldelli A, Bertuzzi F, Davalli AM, Folli F. Autoantibodies against the Glutamate Transporter GLT-1, a specific beta cell plasma membrane protein , in the serum of type I diabetes Subjects. *Diabetologia* 55, pages S201; (Suppl.1); 2012.
 106. Davalli AM, Di Cairano ES, Iaquinto M, Moretti S, Bazzini C, La Rosa S, Bertuzzi F, Folli F, Perego C. The Glutamate Transporter GLT1/EAAT2: a promising target to arrest beta cell dysfunction and death in diabetes mellitus. *Diabetologia* 55, pages S207; (Suppl.1); 2012.
 107. Paez AM, Kamath S, Casiraghi F, Davalli AM, Abrahamian G, Ricotti A, La Rosa S, Comuzzie A, Marando A, Finzi G, Dick E, De Fronzo R, Halff G, Folli F. Chronic exenatide infusion increases insulin sensitivity, decreases insulin secretion and stimulates Islet Cell

- Proliferation in partially Pancreatectomized Baboons. *Diabetologia* 55, pages S291; (Suppl.1); 2012.
108. Tripathy D, Daniele G, Perez-Cadena Z, Chavez A, Kamath S, Andreozzi F, Fiorentino TV, Gastaldelli A, De Fronzo R, Folli F. Low-dose Pioglitazone Improves glycemic control, whole-body and adipocyte insulin resistance and reduces plasma fraktalkine, a novel cytokine in type 2 diabetes. *Diabetologia* 55, pages S326; (Suppl.1); 2012.
 109. Khazim K, D. Giustarini, R. Rossi, D. Verkaik, S. Cunningham, M. Mohammed, K. Trochta, C. Lorenzo, F. Folli, S. Bansal, P. Fanti. Glutathione Redox Potential is Low and Glutathionylated and Cysteinylated Hemoglobin are High in Maintenance Hemodialysis Patients; Association with Routine Parameters of Dietary Intake. (*Submitted for publication*). *ASN KIDNEY WEEK 2012*
 110. F Andreozzi, C Nigro, GA Raciti, C Miele, F Folli. exenatide, a GLP-1 receptor agonist, activates glucose transport in I6 muscle cell line by an AMPK-dependent mechanism. *Diabetes Suppl. 1*; 2013.
 111. TV Fiorentino, F. Casiraghi, AM Paez, S. Kamath, A. Davalli, G. Abrahamian, G. Daniele, F. Andreozzi, AG Comuzzie, E. Dick, RA. Defronzo, G Halff, F. Folli. Chronic exenatide infusion ameliorates insulin signaling in skeletal muscle and liver of partially pancreatectomized baboons *Diabetes Suppl. 1*; 2013.
 112. TV. Fiorentino, M. Owston, G Abrahamian, S Larosa, A Marando, G Finzi, F Sessa, S. Kamath, F Casiraghi, G Daniele, F Andreozzi, AG. Comuzzie, M Sharp, P Williams, RA. Defronzo, G Halff, E Dick, F Folli. Chronic continuous exenatide infusion does not cause pancreatitis or ductal hyperplasia in baboons. A 14 weeks longitudinal controlled study. *Diabetes Suppl. 1*; 2013.
 113. T.V. Fiorentino, G. Daniele, D. Tripathy, Z. Perez-Cadena, A. Chavez Velasquez, S. Kamath, F. Andreozzi, M.L. Hribal, G. Sesti, M. Federici, R.A. DeFronzo, F. Folli. Low dose pioglitazone-induced reduction in skeletal muscle TACE activity and TNF α is associated with an improvement of glycemic control in type 2 diabetic patients. *Diabetologia, Suppl 2013*
 114. G. Daniele, TV Fiorentino, R. Guardado-Mendoza, F. Andreozzi, D. Winnier, C. Jenkison, D. Tripathy. F. Folli. Circulating Osteopontin levels are associated with insulin resistance and inflammation in type 2 diabetes. (*Endocrine Reviews, Volume 34, Issue 3 Supplement*).
 115. G. Daniele, TV Fiorentino, R. Guardado-Mendoza, F. Andreozzi, D. Winnier, C. Jenkinson, D. Tripathy. F. Folli. Inflammation score is associated with insulin resistance but not with insulin secretion in type 2 diabetes. (*Endocrine Reviews, Volume 34, Issue 3 Supplement*)
 116. R. Guardado-Mendoza, C. Perego, L.M. Jimenez-Ceja, G. Finzi, C. Capella, EJ. Dick Jr., Ma. de Lourdes Reyes-Escogido, S. La Rosa, F. Sessa, RA DeFronzo, A Gastaldelli, AM Davalli, F. Folli. Islet Cell Paracrinopathy and the Relevance of Delta-, Alpha- and Beta-Cell Dysfunction in the Development of Hyperglycemia in Non-Human Primates. (*Endocrine Reviews, Volume 35, Issue 3 Supplement*)
 117. V. Fiorentino, M. Owston, G. Abrahamian, S. La Rosa, C. Perego, G. Halff, G. Sesti, R.A. Defronzo, E. Dick, F. Folli. Exenatide non causa pancreatite, iperplasia o displasia duttale e favorisce la neogenesi beta cellulare nel pancreas esocrino di babuino. *25° Congresso Nazionale della Società Italiana di Diabetologia, 2014*
 118. T.V. Fiorentino, S. Kamath, G. Daniele, F. Andreozzi, M.L. Hribal, G. Sesti, R.A. Defronzo, F. Folli. Alterata espressione muscolare di proteine mitocondriali coinvolte nella sintesi di ATP nel diabete mellito tipo 2. *Presentazione orale al 25° Congresso Nazionale della Società Italiana di Diabetologia, 2014*
 119. Perego C, Moretti S, Di Cairano ES, Daniele F, La Rosa S, Bertuzzi F, Davalli A, F. Folli. Modulation of glutamate signalling in human islets of Langerhans under hyperglycaemia. 7-11 September 2014, *Diabetologia, Suppl 2014*
 120. Di Cairano ES, Meraviglia V, Ulivi A, Rosa P, Moretti S, Daniele F., Bertuzzi F, La Rosa S, F. Folli, Sacchi VF, Perego C. Expression and function of the atypical purinergic receptor GPR17 in the endocrine pancreas., *Diabetologia, Suppl 2014*
 121. C.Perego, S.Moretti, E.Di Cairano, F.Daniele, S.Larosa, F.Bertuzzi, A.Davalli, F.Folli. Alterazioni del segnale glutammatergico nell'isola pancreatica umana in condizioni iperglicemiche. Simposio: Meccanismi Molecolari di Patologia. *25° Congresso Nazionale Italiano Società del Diabete. SID 2014.*
 122. C.Perego, S.Moretti, E.Di Cairano, F.Daniele, S.Larosa, F.Bertuzzi, A.Davalli, F.Folli "Rimodellamento dell'isola pancreatica nel diabete di tipo 2: studio in primati non umani".

Simposio: meccanismi molecolari di patologia. 25° Congresso Nazionale Italiano Società del Diabete. SID 2014.

123. Casiraghi F, Caumo A, Benedini S, Luzi L, F. Folli. Exenatide promotes hyperbolic-like specular changes in insulin sensitivity and beta cell function in non human primates-11
124. G. Daniele, D. Winnier, A. Mari, J. Bruder, M. Fourcaudot, Z. Pengou, D. Tripathy, C. Jenkinson, S. Del Prato, F. Folli Sclerostin and Insulin Resistance In Prediabetes. Evidence Of a Cross-Talk Between Bone and Glucose Metabolism. *Congresso Nazionale SIE Taormina 27/30 Maggio 2015*
125. G. Daniele, D. Winnier, A. Mari, J. Bruder, M. Fourcaudot, Z. Pengou, D. Tripathy, C. Jenkinson. F. Folli . Sclerostin and Insulin Resistance In Prediabetes. Evidence Of a Cross-Talk Between Bone and Glucose Metabolism. *Diabetologia, Suppl 2015*
126. D Winnier, G Daniele, A Mari, J Bruder, M Fourcaudot, Z Pengou, D Tripathy, C Jenkinson, F Folli. Bone turnover markers and prediabetes: a cross-sectional study. *Diabetologia, Suppl 2015*
127. C. Perego , S Moretti , C Santi , S LaRosa , F Bertuzzi , F Folli , E.S. Di Cairano. Endocrine cell plasticity in human islets of Langerhans in type 2 diabetes; *Diabetologia, Suppl 2015*
128. ES Di Cairano, S Moretti, F Daniele, V Meraviglia, A Ulivi, P Rosa, F. Bertuzzi, S La Rosa , F Folli , FV Sacchi, C. Perego. Expression and function of the atypical purinergic receptor GPR17 in endocrine pancreas. *Diabetologia, Suppl 2015*
129. F. Folli, V. Uselli, V. Fiorentino, S. Tezza, S. Uccella, M. Ben Nasr, R Bassi, F D'Addio, A Secchi, S La Rosa, P Fiorina. The GLP1R agonist exenatide exerts potent immunomodulatory effects and prolongs heart and islet of Langerhans allograft survival. *Diabetes Suppl. 1; 2016.*
130. F. Folli, F. Casiraghi, L.M. Jimenez Ceja, M. De Lourdes Reyes Escogido, E.J. Dick G. Daniele, A.M. Davalli, T.V. Fiorentino, R. Guardado Mendoza. Physiologic determinants of islet of Langerhans beta, alpha, and δ cell mass in normoglycaemic non human primates *Diabetologia, suppl1; 2016.*
131. TERESA MEZZA, VINSIN A. SUN, FRANCESCA CINTI, GIAN PIO SORICE, CHIARA CEFALO, SIMONA MOFFA, FLAVIA IMPRONTA, SERGIO ALFIERI, FRANCO FOLLI, ANDREA MARI, ANDREA GIACCARI. Beta-cell dysfunction and amplified insulin demand increase the proinsulin/insulin ratio in humans. (*Diabetes Suppl. 2017*)
132. RODOLFO GUARDADO-MENDOZA, PAUL B. HIGGINS, FRANCESCA CASIRAGHI, LILIA M. JIMENEZ-CEJA, EDWARD J. DICK, MA. DE LOURDES REYES-ESCOGIDO, ALBERTO M. DAVALLI, TERESA VANESSA FIORENTINO, FRANCO FOLLI. Physiological determinants of islet β and α cell volume and function in nonhuman primates (*Diabetes Suppl. 2017*)
133. GIOVANNA FINZI, PAUL B. HIGGINS, FRANCESCA CASIRAGHI, EDWARD J. DICK, STEFANO LA ROSA, FAUSTO SESSA, FRANCO FOLLI, intracellular effects of chronic exenatide treatment in islets of langerhans of nonhuman primates after partial pancreatectomy (*Diabetes Suppl. 2017*)
134. C. Berra, F. Zangrandi, F. De Fazio, M. Mirani, G. Favacchio, M. Albini, P. Meroni, F. Folli . Effect of diabetes and glucose variability on fall-risk in hospital population. (*Accepted for Oral/poster presentation – IDF Meeting – Abu Dhabi 2017*)
135. C. Berra, R. Ghelardi, R. Manfrini, P. Bollati, L. Bucciarelli, M. Mirani, M. Muratori, F. Folli and the AWARE study group Cardiovascular risk categories in patients with diabetes according 2019 ESC-EASD guidelines in the clinical practice: use of a dedicate APP (AWARE) (*Accepted for poster presentation ADA 2021*)
- 136.

C. Berra, F. Zangrandi, F. De Fazio, M. Mirani, G. Favacchio, M. Albini, P. Meroni, F. Folli . Effect of diabetes and glucose variability on fall-risk in hospital population. (*Accepted for Oral/poster presentation – IDF Meeting – Abu Dhabi 2017*)

135. C. Berra, R. Ghelardi, R. Manfrini, P. Bollati, L. Bucciarelli, M. Mirani, M. Muratori, F. Folli

and the AWARE study group
Cardiovascular risk categories in patients with diabetes according 2019 ESC-EASD guidelines in
the clinical practice: use of a dedicate APP (AWARE)
(Accepted for poster presentation ADA 2021)